

# meningroupy.txt

? b biochem biosci biotech medicine

? e au=michon, f?

Ref	Items	Index-term
E1	82	AU=MICHON, F
E2	51	AU=MICHON, F.
E3	0	AU=MICHON, F?
E4	144	AU=MICHON, FRANCIS
E5	2	AU=MICHON, FRANCIS J.
E6	2	AU=MICHON, FRANCIS JEAN
E7	1	AU=MICHON, FRANÇIS
E8	6	AU=MICHON, FREDERIC
E9	11	AU=MICHON, G
E10	81	AU=MICHON, G.
E11	1	AU=MICHON, G. J
E12	10	AU=MICHON, G. J.
E13	2	AU=MICHON, G.-J.
E14	2	AU=MICHON, G.J
E15	15	AU=MICHON, G.J.
E16	3	AU=MICHON, GENEVIEVE
E17	1	AU=MICHON, GEORGES
E18	2	AU=MICHON, GERALD
E19	9	AU=MICHON, GERALD J.
E20	1	AU=MICHON, GERARD
E21	1	AU=MICHON, GERARD PHILIPPE
E22	2	AU=MICHON, GILBERT
E23	1	AU=MICHON, GJ
E24	6	AU=MICHON, GUILHEM
E25	6	AU=MICHON, H.

Enter PAGE for more

? s e1-e7

	82	AU=MICHON, F
	51	AU=MICHON, F.
	0	AU=MICHON, F?
	144	AU=MICHON, FRANCIS
	2	AU=MICHON, FRANCIS J.
	2	AU=MICHON, FRANCIS JEAN
	1	AU=MICHON, FRANÇIS
S1	282	S E1-E7

? s s1 and o-acetyl

	282	S1
	181	O-ACETYL
S2	0	S S1 AND O-ACETYL

? s s1 and acetyl

	282	S1
	1352683	ACETYL
S3	34	S S1 AND ACETYL

? rd

>>>w: Duplicate detection is not supported for File 393.  
 Duplicate detection is not supported for File 391.  
 Records from unsupported files will be retained in the RD set.  
 S4 31 RD (UNIQUE ITEMS)

? t s4/3,k/1-34

>>>w: KWIC option is not available in file(s): 399  
 4/3,k/1 (Item 1 from file: 24) Links

CSA Life Sciences Abstracts  
(c) 2009 CSA. All rights reserved.  
0001978949 IP Accession No: 4527872  
Meningococcal polysaccharide conjugate vaccine

Jennings, H; Michon, F National Research Council of Canada  
, May 11, 1999  
Publication Date: 1999

Document Type: Patent  
Record Type: Abstract  
Language: English  
Summary Language: English  
File Segment: Medical & Pharmaceutical Biotechnology Abstracts  
Jennings, H; Michon, F

Abstract:

Neisseria meningitidis group B polysaccharide (GBMP) modified by having sialic acid residue N-acetyl groups replaced by N-acyl groups exhibits enhanced immuno response thereto. In addition, induction of...

4/3,K/2 (Item 2 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts  
(c) 2009 CSA. All rights reserved.  
0001719133 IP Accession No: 4045120

Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates

Fusco, PC; Michon, F; Tai, JY; Blake, MS North American Vaccine, Inc., 12103 Indian Creek Ct., Beltsville, MD 20705, USA  
Journal of Infectious Diseases , v 175 , n 2 , p 364-372 , February 1997  
Publication Date: 1997

Document Type: Journal Article  
Record Type: Abstract  
Language: English  
Summary Language: English  
ISSN: 0022-1899  
File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts  
Fusco, PC; Michon, F; Tai, JY; Blake, MS

Abstract:

...activity was also confirmed with human and monkey complement. IgG cross-reactivity for unmodified N-acetyl polysaccharide was <5% for 79% of mice and <10% for 80% of primates. These studies...

4/3,K/3 (Item 3 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts  
(c) 2009 CSA. All rights reserved.  
0000603563 IP Accession No: 1595972

Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid *Staphylococcus aureus* .

Lee, JC; Michon, F; Perez, NE; Hopkins, CA; Pier, GB Channing Lab., Brigham and Women's Hosp., Boston, MA 02115, USA  
Infection and Immunity , v 55 , n 9 , p 2191-2197 , 1987  
Addl. Source Info: Infection and Immunity [INFECT. IMMUN.], vol. 55, no. 9, pp.

2191-2197, 1987

Publication Date: 1987

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English

ISSN: 0019-9567

File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts

Lee, JC; Michon, F; Perez, NE; Hopkins, CA; Pier, GB

Abstract:

...ethanol precipitations and enzyme digestions, followed by ion-exchange chromatography. The polysaccharide also contained O-acetyl groups which were removed by mild alkaline hydrolysis. Serologically and biochemically, the capsule from strain...

4/3,K/4 (Item 4 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts

(c) 2009 CSA. All rights reserved.

0000319743 IP Accession No: 828591

Structural elucidation of the capsular polysaccharide of Neisseria meningitidis group H.

Michon, F; Roy, R; Jennings, HJ; Ashton, FE Div. Biol. Sci., Natl. Res. Coun. of Canada, Ottawa, Ont., Canada K1A 0R6

Canadian Journal of Chemistry/Revue Canadienne de Chimie, v 62, n 8, p 1519-1524, 1984

Add. Source Info: Canadian Journal of Chemistry [CAN. J. CHEM.], vol. 62, no. 8, pp. 1519-1524, 1984

Publication Date: 1984

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English; French

ISSN: 0008-4042

File Segment: Bacteriology Abstracts (Microbiology B); Industrial & Applied

Microbiology Abstracts (Microbiology A)

Michon, F; Roy, R; Jennings, HJ; Ashton, FE

Abstract:

...1:1 and is composed of a basic repeating unit. The polysaccharide contains O-acetyl groups, in the molar ratio of 0.8:1.0 with D-galactose, which are... of the major group specific determinant based on serological experiments described. Although all the O-acetyl groups are located on D-galactopyranosyl residues, the substitution pattern is complex, 60% of the...

4/3,K/5 (Item 1 from file: 305) Links

Fulltext available through: STIC Full Text Retrieval Options

Analytical Abstracts

(c) 2009 Royal Soc Chemistry. All rights reserved.

380576 AA Accession No.: 66-30-F-10127 Doc. Type: Journal

An integrity assay for a meningococcal type B conjugate vaccine.

Author: Turula, V. E. ; Kim, J. ; Michon, F. ; Pankratz, J. ; Zhang, Y. W. ; Yoo, C.

Corporate Source: vinnie turula@baxter.com, BioSci. Div., Baxter Healthcare Corp.,

Beltsville, MD 20705, USA

Journal: Anal. Biochem. , ( Analytical Biochemistry ), Volume: 327, Issue: 2, Pages: 261-270

CODEN: ANBCA2 ISSN: 0003-2697

Publication Date: 15 Apr 2004 ( 20040415 ) Language: English

Author: Turula, V. E. ; Kim, J. ; Michon, F. ; Pankratz, J. ; Zhang, Y. W. ; Yoo, C.

Abstract: ...of the methanolysis reaction was a de-N-acylated methyl glycoside of sialic acid. N-acetylneuraminic acid oligomers and colominic acid were used to confirm the methanolysis depolymerization efficiency of the...

4/3,K/6 (Item 1 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5683341

Title: Structural determination of the group K capsular polysaccharide of *Neisseria meningitidis*: a 2D-NMR analysis

Document Type: Journal Record Type: Abstract

Author: Michon, Francis; Brisson, Jean Robert; Roy, Rene; Jennings, Harold J.;

Ashton, Fraser E.

Citation: Can.J.Chem. (1985) Series: 63, 2781-2786 CODEN: CJCCHG Language: English

Abstract Language: English

Author: Michon, Francis; Brisson, Jean Robert; Roy, Rene; Jennings, Harold J.;

Ashton, Fraser E.

Patent Assignee:

Abstract: ... generated by the presence of contiguous carboxylated sugar residues in the K polysaccharide. The O-acetyl substituents of the K polysaccharide are essential for its antigenicity to group K polysaccharide-specific...

Abstract Language:

4/3,K/7 (Item 2 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5680514

Title: KINETIC STUDIES ON THE REARRANGEMENT OF 3,4-DI-O-BENZYL-1,2-O-(1-METHOXYETHYLIDENE)- beta -L-RHAMNOPYRANOSE WITH A CATALYTIC AMOUNT OF 1,1,3,3-TETRAMETHYLLUREA-TRIFLUOROMETHANESULFONIC ACID AT DIFFERENT TEMPERATURES

Document Type: Journal Record Type: Abstract

Author: Banoub, Joseph H.; Michon, Francis; Rice, Jake; Rateb, Latif

Citation: Carbohydr. Res. (1983) Series: 123, 109-116 CODEN: CRBRAT Language: English

Abstract Language: English

Author: Banoub, Joseph H.; Michon, Francis; Rice, Jake; Rateb, Latif

Patent Assignee:

Abstract: ... di-o-benzyl-1,2-O-(1-methoxyethylidene)- beta -L-rhamnopyranose to methyl 2-O-acetyl-3,4-di-o-benzyl- alpha -L-rhamnopyranoside with a catalytic amount of 1,1...

Abstract Language:

4/3,K/8 (Item 3 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5680082

Title: E.I. AND C.I. MASS-SPECTRAL IDENTIFICATION OF SOME DERIVATIVES OF 7-O-(2-AMINO-2-DEOXY- alpha -D-GLUCOPYRANOSYL)-L-glycero-D-mann o-HEPTOSE, OBTAINED FROM LIPOPOLYSACCHARIDES REPRESENTATIVE OF THE Vibrionaceae FAMILY

Document Type: Journal Record Type: Abstract

Author: Banoub, Joseph H.; Michon, Francis; Shaw, Derek H.; Roy, Rene

Citation: Carbohydr. Res. (1984) Series: 128, 203-216 CODEN: CRBRAT Language: English

Abstract Language: English

Author: Banoub, Joseph H.; Michon, Francis; Shaw, Derek H.; Roy, Rene

Patent Assignee:

Abstract: ...chemical-ionization (c.i.) mass spectra of the 2-di-N-methyl (2), 2-N-acetyl (3), and 2-(N-acetyl)-N-methyl (4) derivatives of 1,5-di-O-acetyl-7-O-(2-amino-2-deoxy-3,4, 6-tri-O-methyl- alpha -D-glucopyranosyl)... spectra and fragmentation pattern of methyl 7-O-(2-acetamido-3,4,6-tri-O-acetyl -2-deoxy- alpha -D-glucopyranosyl)-2,3,4,6-tetra-O-acetyl -L-glycero- alpha -D-manno-heptopyranoside (6) are also reported.

Abstract Language:

4/3,K/9 (Item 4 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5673899

Title: Structural elucidation of the capsular polysaccharide of Neisseria meningitidis group H 1

Document Type: Journal

Record Type: Abstract

Author: Michon, Francis; Roy, Rene; Jennings, Harold J.; Ashton, Fraser E.

Citation: Can.J.Chem. (1984) Series: 62, 1519-1524 CODEN: C3CHAG Language: English

Abstract Language: English

Author: Michon, Francis; Roy, Rene; Jennings, Harold J.; Ashton, Fraser E.

Patent Assignee:

Abstract: ... 1 and is composed of the following basic repeating unit: (formula) The polysaccharide contains O-acetyl groups, in the molar ratio of 0.8:1.0 with D-galactose, which are... of the major group specific determinant based on serological experiments described. Although all the O-acetyl groups are located on D-galactopyranosyl residues, the substitution pattern is complex, 60 percent of... Abstract Language:

4/3,K/10 (Item 5 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5670468

Title: Formation of 3,4-di-O-acetyl-1,6-anhydro-2,7-di-O-methyl-L-glycero-D-manno-heptopyranose during methylation analysis of lipopolysaccharide cores representative of the Vibrionaceae family

Document Type: Journal

Record Type: Citation

Author: Banoub, Joseph H.; Michon, Francis; Shaw, Derek H.

Citation: Carbohydr.Res. (1985) Series: 138, 171-176 CODEN: CRBRAT Language: English

Title: Formation of 3,4-di-O-acetyl-1,6-anhydro-2,7-di-O-methyl-L-glycero-D-manno-heptopyranose during methylation...

Document Type:

Author: Banoub, Joseph H.; Michon, Francis; Shaw, Derek H.

Patent Assignee:

4/3,K/11 (Item 6 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5611940

Title: A rapid, g.l.c.-m.s. method for identification of the N-acetyl group of amino sugars in complex carbohydrates

Document Type: Journal

Record Type: Citation

Author: Banoub, Joseph H.; Michon, Francis

Citation: Carbohydr.Res. (1982) Series: 100, C24-C26 CODEN: CRBRAT Language: English

Title: A rapid, g.l.c.-m.s. method for identification of the N-acetyl group of amino sugars in complex carbohydrates

Document Type:

meningroupy.txt  
Author: Banoub, Joseph H.; Michon, Francis  
Patent Assignee:

4/3,K/12 (Item 1 from file: 399) Links  
CA SEARCH(R)  
(c) 2009 American Chemical Society. All rights reserved.

147137083 CA: 147(7)137083c PATENT  
Method for purifying polysaccharides from cellular components with acid or base reagents  
Inventor (Author): Michon, Francis; Uitz, Catherine  
Location: USA  
Assignee: Baxter International Inc.; Baxter Healthcare S.A.  
Patent: U.S. Pat. Appl. Publ. ; US 20070154492 A1 Date: 20070705  
Application: US 2007622906 (20070112) \*US 2006PV758894 (20060113)  
Pages: 25pp.  
CODEN: USXXCO  
Language: English  
Patent Classifications:  
Class: 424234100

IPCR/8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0039/08	A	I F B	20060101	20070705	H	US	
A61K-0039/02	A	I L B	20060101	20070705	H	US	
C08B-0037/00	A	I L B	20060101	20070705	H	US	
C12P-0019/28	A	I L B	20060101	20070705	H	US	

4/3,K/13 (Item 2 from file: 399) Links  
Fulltext available through: STIC Full Text Retrieval Options  
CA SEARCH(R)  
(c) 2009 American Chemical Society. All rights reserved.

147008030 CA: 147(1)8030j JOURNAL  
Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation  
Author: Fusco, Peter C.; Farley, Esme K.; Huang, Chun-Hsien; Moore, Samuel; Michon, Francis  
Location: BioVeris Corporation, Gaithersburg, MD, 20877, USA  
Journal: Clin. Vaccine Immunol.  
Date: 2007  
Volume: 14 Number: 5 Pages: 577-584  
CODEN: CVILAE  
ISSN: 1556-6811  
Language: English  
Publisher: American Society for Microbiology

? s (lack or loss) and acetyl  
>>>W: KWIC option is not available in file(s): 399  
>>>E: There is no result

? b biochem biosci biotech medicine  
>>>E: Object error, please notify DialogCustomer@Thomson.com, your session is ready to continue

? Logoff  
>>>F: User not logged in or session timeout

? Logon  
\*\*\* It is now 1/16/2009 11:49:14 PM \*\*\*  
welcome to DialogLink - Version 5

Revolutionize the Way You Work!

#### New on Dialog

Order Patent and Trademark File Histories Through Dialog  
Thomson File Histories are now available directly through Dialog. Combined with the comprehensive patent and trademark information on Dialog, file histories give you the most complete view of a patent or trademark and its history in one place. When searching in the following patent and trademark databases, a link to an online order form is displayed in your search results, saving you time in obtaining the file histories you need.

Thomson File Histories are available from the following Dialog databases:

CLAIMS/Current Patent Legal Status (File 123)  
CLAIMS/U.S. Patents (File 340)  
Chinese Patent Abstracts in English (File 344)  
Derwent Patents Citation Index (File 342)  
Derwent World Patents Index (for users in Japan) (File 352)  
Derwent World Patents Index First View (File 331)  
Derwent World Patents Index (File 351)  
Derwent World Patents Index (File 350)  
Ei EnCompassPat (File 353)  
European Patents Fulltext (File 348)  
French Patents (File 371)  
German Patents Fulltext (File 324)  
IMS Patent Focus (File 447, 947)  
INPADOC/Family and Legal Status (File 345)  
JAPIO - Patent Abstracts of Japan (File 347)  
LitAlert (File 670)  
U.S. Patents Fulltext (1971-1975) (File 652)  
U.S. Patents Fulltext (1976-present) (File 654)  
WIPO/PCT Patents Fulltext (File 349)  
TRADEMARKSCAN - U.S. Federal (File 226)

#### DialogLink 5 Release Notes

New features available in the latest release of DialogLink 5 (August 2006)  
Ability to resize images for easier incorporation into DialogLink Reports  
New settings allow users to be prompted to save Dialog search sessions in the format of their choice (Microsoft Word, RTF, PDF, HTML, or TEXT)  
Ability to set up Dialog Alerts by Chemical Structures and the addition of Index Chemicus as a structure searchable database  
Support for connections to STN Germany and STN Japan services

Show Preferences for details

? Help Off Line

\* \* \*

Connecting to N. Archie - Dialog - 294084

Connected to Dialog via SMS004024517

? b biochem biosci biotech medicine

[File 5] Biosis Previews(R) 1926-2009/Jan w2

(c) 2009 The Thomson Corporation. All rights reserved.

[File 6] NTIS 1964-2009/Jan w3

(c) 2009 NTIS, Intl Cpyrght All Rights Res. All rights reserved.

[File 24] CSA Life Sciences Abstracts 1966-2009/Dec

(c) 2009 CSA. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2009/Jan w1

(c) 2009 The Thomson Corp. All rights reserved.

meningroupy.txt

[File 40] Enviroline(R) 1975-2008/May

(c) 2008 Congressional Information Service. All rights reserved.

\*File 40: This file is closed and will no longer update. For similar data, please search File 76-Environmental Sciences.

[File 41] Pollution Abstracts 1966-2009/Dec

(c) 2009 CSA. All rights reserved.

[File 45] EMCare 2009/Jan w2

(c) 2009 Elsevier B.V. All rights reserved.

[File 50] CAB Abstracts 1972-2009/Jan w2

(c) 2009 CAB International. All rights reserved.

\*File 50: The file has been reloaded and accession numbers have changed. See HELP NEWS50 for information.

[File 65] Inside Conferences 1993-2009/Jan 16

(c) 2009 BLDSC all rts. reserv. All rights reserved.

[File 71] ELSEVIER BIOBASE 1994-2009/Dec w4

(c) 2009 Elsevier B.V. All rights reserved.

\*File 71: The file has been reloaded. Accession numbers have changed.

[File 72] EMBASE 1993-2009/Jan 15

(c) 2009 Elsevier B.V. All rights reserved.

[File 73] EMBASE 1974-2009/Jan 16

(c) 2009 Elsevier B.V. All rights reserved.

[File 76] Environmental Sciences 1966-2009/Dec

(c) 2009 CSA. All rights reserved.

[File 98] General Sci Abs 1984-2008/Dec

(c) 2008 The HW Wilson Co. All rights reserved.

[File 103] Energy SciTec 1974-2009/Dec B2

(c) 2009 Contains copyrighted material. All rights reserved.

\*File 103: For access restrictions see Help Restrict.

[File 136] BioEngineering Abstracts 1966-2007/Jan

(c) 2007 CSA. All rights reserved.

\*File 136: This file is closed.

[File 143] Biol. & Agric. Index 1983-2009/Dec

(c) 2009 The HW Wilson Co. All rights reserved.

[File 144] Pascal 1973-2008/Dec w3

(c) 2008 INIST/CNRS. All rights reserved.

[File 154] MEDLINE(R) 1990-2008/Dec 15

(c) format only 2009 Dialog. All rights reserved.

\*File 154: Medline has resumed updating with UD20081211.

[File 155] MEDLINE(R) 1950-2008/Dec 12

(c) format only 2009 Dialog. All rights reserved.

\*File 155: Medline has resumed updating with UD20081211.

[File 156] ToxFile 1965-2008/Nov w2

(c) format only 2008 Dialog. All rights reserved.

\*File 156: The file has temporarily ceased updating with Medline records as Medline has, in preparation for its annual reload.

[File 162] Global Health 1983-2009/Jan w2

(c) 2009 CAB International. All rights reserved.

\*File 162: The file has been reloaded and accession numbers have changed. See HELP NEWS 162 for information.

[File 172] EMBASE Alert 2009/Jan 16

(c) 2009 Elsevier B.V. All rights reserved.

[File 305] Analytical Abstracts 1980-2009/Dec w4

(c) 2009 Royal Soc Chemistry. All rights reserved.

\*File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.

[File 369] New Scientist 1994-2009/Jan w1

(c) 2009 Reed Business Information Ltd. All rights reserved.

[File 370] Science 1996-1999/Jul w3

(c) 1999 AAAS. All rights reserved.

\*File 370: This file is closed (no updates). Use File 47 for more current information.

[File 393] Beilstein Database - Abstracts 2008/Q2

(c) 2008 Beilstein GmbH. All rights reserved.



meningroupy.txt

[File 399] CA SEARCH(R) 1967-2009/UD=15003  
(c) 2009 American Chemical Society. All rights reserved.  
\*File 399: Use is subject to the terms of your user/customer agreement. IPCR/8  
classification codes now searchable as IC=. See HELP NEWSIPCR.  
[File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 2006 The Thomson Corp. All rights reserved.  
[File 28] Oceanic Abstracts 1966-2009/Jan  
(c) 2009 CSA. All rights reserved.  
[File 35] Dissertation Abs Online 1861-2008/Nov  
(c) 2008 ProQuest Info&Learning. All rights reserved.  
[File 44] Aquatic Science & Fisheries Abstracts 1966-2009/Jan  
(c) 2009 CSA. All rights reserved.  
[File 91] MANTIS(TM) 1880-2008/Aug  
2001 (c) Action Potential. All rights reserved.  
\*File 91: The supplier is changing formats so the file is temporarily not updating.  
[File 110] WasteInfo 1974-2002/Jul  
(c) 2002 AEA Techn Env. All rights reserved.  
\*File 110: This file is closed (no updates)  
[File 135] NewsRx Weekly Reports 1995-2009/Jan w1  
(c) 2009 NewsRx. All rights reserved.  
[File 164] Allied & Complementary Medicine 1984-2009/Jan  
(c) 2009 BLHCIS. All rights reserved.  
[File 185] Zoological Record Online(R) 1864-2009/Jan  
(c) 2009 The Thomson Corp. All rights reserved.  
[File 357] Derwent Biotech Res. 1982-2008/Nov w5  
(c) 2008 Thomson Reuters. All rights reserved.  
[File 391] Beilstein Database - Reactions 2008/Q2  
(c) 2008 Beilstein GmbH. All rights reserved.  
[File 467] Extramed(tm) 2000/Dec  
(c) 2001 Informania Ltd. All rights reserved.  
[File 8] Ei Compendex(R) 1884-2009/Jan w1  
(c) 2009 Elsevier Eng. Info. Inc. All rights reserved.  
[File 99] Wilson Appl. Sci & Tech Abs 1983-2009/Dec  
(c) 2009 The HW Wilson Co. All rights reserved.  
[File 266] FEDRIP 2008/Nov  
Comp & dist by NTIS. Intl Copyright All Rights Res. All rights reserved.  
[File 315] ChemEng & Biotech Abs 1970-2008/Dec  
(c) 2008 DECHEMA. All rights reserved.  
\*File 315: December 2007 - the reloaded database is now online. Please consult the  
updated Bluesheet for details on new and changed fields.  
[File 358] Current BioTech Abs 1983-2006/Jan  
(c) 2006 DECHEMA. All rights reserved.  
\*File 358: This file is no longer updating. Please use File 315, which includes all  
File 358 records and updates.  
[File 138] Physical Education Index 1990-2009/Jan  
(c) 2009 CSA. All rights reserved.  
[File 149] TGG Health&Wellness DB(SM) 1976-2009/Dec w1  
(c) 2009 Gale/Cengage. All rights reserved.  
[File 159] Cancerlit 1975-2002/Oct  
(c) format only 2002 Dialog. All rights reserved.  
[File 444] New England Journal of Med. 1985-2009/Sep w4  
(c) 2009 Mass. Med. Soc. All rights reserved.

? s (loss or lack) and acetyl

4523031 LOSS  
2125725 LACK  
1352683 ACETYL

S1 25686 S (LOSS OR LACK) AND ACETYL

? s s1 and menin?

25686 S1

meningroupy.txt

S2 556587 MENIN?  
169 S S1 AND MENIN?

? rd

>>>W: Duplicate detection is not supported for File 393.  
Duplicate detection is not supported for File 391.  
Records from unsupported files will be retained in the RD set.  
S3 77 RD (UNIQUE ITEMS)

? s ((menin? and (OAC or o-acetyl))  
>>>W: Unmatched parentheses  
>>>E: There is no result

? s (menin? and (OAC or o-acetyl))  
556587 MENIN?  
102311 OAC  
181 O-ACETYL  
S4 124 S (MENIN? AND (OAC OR O-ACETYL))

? rd

>>>W: Duplicate detection is not supported for File 393.  
Duplicate detection is not supported for File 391.  
Records from unsupported files will be retained in the RD set.  
S5 37 RD (UNIQUE ITEMS)

? t s5/3,k/1-37

>>>W: KWIC option is not available in file(s): 399  
5/3,k/1 (Item 1 from file: 5) Links  
Fulltext available through: STIC Full Text Retrieval Options  
Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0020217670 Biosis No.: 200800264609

Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors

Author: Ariga Toshio; Suetake Keiji; Nakane Makoto; Kubota Masaru; Usuki Seigo;  
Kawashima Ikuo; Yu Robert K (Reprint)  
Author Address: Med Coll Georgia, Inst Mol Med and Genet, 1120 15th St, Augusta, GA  
30912 USA\*\*USA

Author E-mail Address: ryu@mcg.edu  
Journal: NeuroSignals 16 ( 2-3 ): p 226-234 2008 2008

Item Identifier: doi:10.1159/000111565

ISSN: 1424-862X

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...quantitative HPTLC immunostaining. Among the Among the gangliosides surveyed, GD3 and 9-O-acetylated GD3 (OAC-GD3) were expressed in all tumor cell lines. In contrast, fucosyl-GM1 was not found... ..lung carcinoma cells. In addition, we have analyzed serum antibody titers against SGPG, GD3, and OAC-GD3 in patients with neural tumors by ELISA and HPTLC immunostaining. All sera had high... ..the IGM isotype against SGPG (titers over 1: 3,200), especially in tumors such as meningiomas, germinomas, orbital tumors, glioblastomas, medulloblastomas, and subependymomas. Serum in a patient with subependymomas also had... ..with subependymomas and medulloblastomas; the latter cases also had a high titer of antibody against OAC-GD3. Our data indicate that certain GSL antigens, especially SGLs, GD3, and OAC-GD3, are expressed in neural tumor cells and may be considered as tumor-associated antigens...

5/3,k/2 (Item 2 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options  
Page 10

Biosis Previews(R)

(C) 2009 The Thomson Corporation. All rights reserved.

0019996075 Biosis No.: 200800043014

Comparison of *Neisseria meningitidis* serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide

Author: Gudlavalleti Seshu K (Reprint); Lee Che-Hung; Norris Scott E;

Paul-Satyaseela Maneesh; Vann Willie F; Frasc Carl E

Author Address: US FDA, Ctr Biol Evaluat and Res, Lab Bacterial Polysaccharides, Room 109,Bldg 29,Lincoln Dr, Bethesda, MD 20892 USA\*\*USA

Author E-mail Address: gudlavalletis@yahoo.com

Journal: Vaccine 25 ( 46 ): p 7972-7980 NOV 14 2007 2007

Item Identifier: doi:10.1016/j.vaccine.2007.06.018

ISSN: 0264-410X

Document Type: Article

Record Type: Abstract

Language: English

Comparison of *Neisseria meningitidis* serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non...

**Abstract:** Polysaccharide (PS) and tetanus toxoid (TT) protein conjugate vaccines were prepared using O-acetylated (OAC+), O-acetyl negative (OAC-) and chemically de-O-acetylated (de-OAC) meningococcal W135 PS. The PSs were activated by periodate oxidation and coupled to hydrazine derivatized TT... ..exchange chromatography of acid hydrolysates of periodate activated W135 PSs, showed that galactose residues in OAC+ PS were more sensitive to the periodate oxidation step than they were in the OAC- PS or de- OAC PS. Mouse antisera against OAC--TT conjugate vaccines recognized both OAC- and OAC+ PS by ELISAs and had high bactericidal titers against both OAC+ and OAC- W135 strains. Purified high molecular weight (HMW) conjugates showed higher PS to protein ratios in OAC+--TT(HMW) and (HMW) conjugate. Antisera against the HMW fractions gave higher de-OAC--TT(HMW) indicating better conjugation efficiency than OAC+--TT(HMW) bactericidal titers than antisera against unfractionated conjugates. Inhibition ELISAs indicated that OAC- and OAC+ HMW conjugates induced antibodies that bound both OAC+ and OAC- PS. Thus, for W135, PS O-acetylation does not contribute a dominant immunogenic epitope. The OAC- PS may be a good starting material for preparing W135 PS-TT conjugate vaccines using...

DESCRIPTORS:

Organisms: ...*Neisseria meningitidis* (Neisseriaceae...)

Organisms: Parts Etc:

Diseases: *Neisseria meningitidis* infection...

Mesh Terms:

5/3,K/3 (Item 3 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(C) 2009 The Thomson Corporation. All rights reserved.

0019741080 Biosis No.: 200700400821

Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation

Author: Fusco Peter C (Reprint); Farley Esme K; Huang Chun-Hsien; Moore Samuel; Michon Francis

Author Address: BioVeris Corp, 16020 Ind Dr, Gaithersburg, MD 20877 USA\*\*USA

Author E-mail Address: pfusco@bioveris.com; fmichon@bioveris.com

Journal: Clinical and Vaccine Immunology 14 ( 5 ): p 577-584 MAY 2007 2007

Item Identifier: doi:10.1128/CVI.00009-07

ISSN: 1556-6811

Document Type: Article

Record Type: Abstract

Language: English

meningroupy.txt

Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation

Abstract: Previous studies with group C meningococcal polysaccharide-tetanus toxoid (GCMP-TT) conjugates had suggested that the GCMP O-acetyl group masked the protective epitope for group C meningococci through steric hindrance or altered conformations. For this report, we confirmed this phenomenon and performed comparative studies with group Y meningococcal polysaccharide (GYMP)-TT to determine whether it might extend to other serogroups. The de-O... ..dOA) polysaccharides (PSS) resulted in higher serum bactericidal activities (SBA) towards the O-acetylated (OA) meningococcal strains from the respective serogroups. High-resolution H-nuclear magnetic resonance spectroscopy at 500 MHz... ..generalized role for the O-acetyl group to provide an epitope of misdirected immunogenicity for meningococcal PS capsules, enabling escape from immune surveillance. In addition to greater chemical consistency, the dOA...

DESCRIPTORS:

Organisms: ...Neisseria meningitidis (Neisseriaceae...)

Organisms: Parts Etc: ...meningococcal capsule

Diseases: meningococcal disease...

Mesh Terms: Meningococcal Infections (MeSH)

Chemicals & Biochemicals: ...O-acetyl... ..group Y meningococcal polysaccharide-TT

5/3,K/4 (Item 4 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

18936659 Biosis No.: 200600282054

In vivo determination of Neisseria meningitidis serogroup A capsular polysaccharide by whole cell high-resolution magic angle spinning NMR spectroscopy

Author: Gudlavalleti Seshu K; Szymanski Christine M; Jarrell Harold C; Stephens David S (Reprint)

Author Address: Dept Vet Affairs Med Ctr, 1670 Clarimont Rd, Atlanta, GA 30033 USA\*\*USA

Author E-mail Address: dstep01@emory.edu

Journal: Carbohydrate Research 341 ( 4 ): p 557-562 MAR 20 2006 2006

ISSN: 0008-6215

Document Type: Article

Record Type: Abstract

Language: English

In vivo determination of Neisseria meningitidis serogroup A capsular polysaccharide by whole cell high-resolution magic angle spinning NMR spectroscopy

Abstract: High resolution-magic angle spinning (HRMAS) NMR spectroscopy was applied to serogroup A Neisseria meningitidis (NMA) to determine precise structures of capsular polysaccharide (CPS) expressed on the meningococcal surface. Both the O-acetylated (OAC) NMA parent and a mynC::opha3 OAC- mutant demonstrated characteristic CPS-derived NMR signals indicating cell-surface expression of CPS, but only ...

DESCRIPTORS:

Organisms: Neisseria meningitidis (Neisseriaceae...)

Organisms: Parts Etc:

5/3,K/5 (Item 5 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

17950093 Biosis No.: 200400320850

meningroupy.txt

Surface plasmon resonance analysis of antipolysaccharide antibody specificity:  
Responses to meningococcal group C conjugate vaccines and bacteria

Author: Garcia-Ojeda Pablo A; Hardy Sharon; Kozlowski Steven; Stein Kathryn E;  
Feavers Ian M (Reprint)  
Author Address: Div Bacteriol, Natl Inst Biol Stand and Controls, Blanche Ln, Potters  
Bar, Potters Bar, Herts, EN6 3QG, England\*\*England  
Author E-mail Address: ifeavers@nibsc.ac.uk  
Journal: Infection and Immunity 72 ( 6 ): p 3451-3460 June 2004 2004  
Medium: print  
ISSN: 0019-9567 \_(ISSN print)  
Document Type: Article  
Record Type: Abstract  
Language: English  
Surface plasmon resonance analysis of antipolysaccharide antibody specificity:  
Responses to meningococcal group C conjugate vaccines and bacteria

Abstract: Antibody (Ab) responses to polysaccharides (PS), such as *Neisseria meningitidis* group C PS (MCPS), are characterized as being thymus independent and are restricted with regard... ..plasmon resonance approach to evaluate Ab responses to MCPS conjugate vaccines, including either O-acetylated (OAC+) or de-O-acetylated (OAC-) forms of the PS. The results were generally consistent with those obtained by enzyme-linked... ..that sera from mice immunized with conjugate vaccines contain Abs that bind more effectively to OAC+ and OAC- MCPS than sera from mice immunized with fixed bacteria. The data suggest a critical shared...

DESCRIPTORS:

Organisms: ...*Neisseria meningitidis* {meningococcus} (Neisseriaceae...

Organisms: Parts Etc:

Diseases: meningococcal infection...

Mesh Terms:

Chemicals & Biochemicals: ...meningococcal group C conjugate vaccines

5/3,K/6 (Item 6 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(C) 2009 The Thomson Corporation. All rights reserved.

17136004 Biosis No.: 200300094723

Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.

Author: Harris Shannon L; King W James; Ferris Wendy; Granoff Dan M (Reprint)

Author Address: 5700 Martin Luther King Jr. Way, Oakland, CA, 94609, USA\*\*USA

Author E-mail Address: dgranoff@chori.org

Journal: Infection and Immunity 71 ( 1 ): p 275-286 January 2003 2003

Medium: print

ISSN: 0019-9567 \_(ISSN print)

Document Type: Article

Record Type: Abstract

Language: English

Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.

Abstract: Serum bactericidal activity confers protection against meningococcal disease, but it is not known whether vaccine-induced anticapsular antibodies that lack bactericidal activity... ..developed an infant rat challenge model using a naturally occurring O-acetylated strain of *Neisseria meningitidis* group C and a strain that was negative for O acetylation (OAC). Rats 4 to 7 days of age inoculated intraperitoneally (i.p.) with approx 10<sup>3</sup> CFU of... ..no effect on bacteremia, whereas group C anticapsular antibody in sera from adults immunized with meningococcal polysaccharide vaccine conferred complete or partial (>99% decrease in CFU per

meningroupy.txt

milliliter of blood) protection against the OAC-positive or OAC-negative strain, respectively, at antibody doses as low as 0.04 mug/rat. Anticapsular antibody...  
...antibody avidity. Thus, not only does the magnitude of the group C antibody response to meningococcal polysaccharide vaccine increase with increasing age but there are also age-related effects on antibody...

DESCRIPTORS:

Organisms: Neisseria meningitidis (Neisseriaceae...

Organisms: Parts Etc:

Diseases: meningococcal disease...

Mesh Terms: Meningococcal Infections (MeSH...

Chemicals & Biochemicals: ...meningococcal polysaccharide vaccine

5/3,K/7 (Item 7 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16040848 Biosis No.: 200100212687

Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains

Author: Richmond Peter (Reprint); Borrow Ray; Findlow Jamie; Martin Sarah; Thornton

Carol; Cartwright Keith; Miller Elizabeth

Author Address: Department of Paediatrics, University of Western Australia, Princess

Margaret Hospital for Children, Perth, WA, 6014, Australia\*\*Australia

Journal: Infection and Immunity 69 ( 4 ): p 2378-2382 April, 2001 2001

Medium: print

ISSN: 0019-9567

Document Type: Article

Record Type: Abstract

Language: English

Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming, and bactericidal activity...

Abstract: The polysaccharide capsule of serogroup C Neisseria meningitidis (MenC) has been integral to vaccine development. Licensed MenC vaccines contain the O-acetylated (OAC+) form of polysaccharide. Some MenC strains have de-O-acetylated (OAC-) polysaccharide, which may affect antibody specificity and functional activity when used in a vaccine. We evaluated an OAC-MenC conjugate-tetanus toxoid conjugate (MCC-TT) vaccine given concomitantly with whole-cell diphtheria-tetanus... ..83 infants at 2, 3, and 4 months of age. Serum bactericidal activities (SBA) against OAC+ and OAC- MenC strains and OAC+ and OAC- polysaccharide-specific immunoglobulin G (IgG) levels were evaluated. MCC-TT vaccine was well tolerated. All... ..after a single dose at 2 months of age. The SBA geometric mean titer for OAC+ strain C11 increased from 2.7 (95% confidence interval (CI) 2.2 to 3.2... ..95% CI, 856 to 1319) after one, two, and three doses of MCC-TT, respectively. OAC- IgG levels were twice as high as OAC+ IgG levels after the primary series of MCC-TT vaccine, and the SBA was significantly higher against the OAC- MenC strain. Antibody responses to booster vaccination with either OAC+ MenC polysaccharide vaccine (MACP) or a fourth dose of MCC-TT at 14 months of... ..acetylation status of the booster vaccine influenced the specificity of the response, with significantly higher OAC- IgG levels and SBA after MCC-TT vaccine compared to MACP vaccine but similar OAC+ antibody levels. MCC-TT vaccine is highly immunogenic and primes for immunologic memory against OAC+ and OAC- MenC strains in infancy.

DESCRIPTORS:

Organisms: ...Neisseria meningitidis (Neisseriaceae...

Organisms: Parts Etc:

Chemicals & Biochemicals: de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate...

5/3,K/8 (Item 8 from file: 5) Links  
Fulltext available through: STIC Full Text Retrieval Options  
Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.  
15985291 Biosis No.: 200100157130  
Synthesis of Haemophilus influenzae carbohydrate surface antigens

Author: Oscarson S (Reprint)  
Author Address: Department of Organic Chemistry, Arrhenius Laboratory, University of Stockholm, S-106 91, Stockholm, Sweden\*\*Sweden  
Journal: Carbohydrate Polymers 44 ( 4 ): p 305-311 April, 2001 2001  
Medium: print  
ISSN: 0144-8617  
Document Type: Article; Literature Review  
Record Type: Abstract  
Language: English

Abstract: The pathogenic bacteria Haemophilus influenzae, causing, i.a., meningitis and otitis, contain both capsular and lipopolysaccharide surface antigens. The syntheses of several oligosaccharides corresponding ... and trimers of the repeating unit of the capsular polysaccharides of serotype c, (-4)-3-OAc-beta-D-GlcpNAC-(1variant phi3)-alpha-D-Galp-(1-PO3--) and serotype f(-3)-beta-D-GalpNAC-(1variant phi4)-3-OAc-alpha-D-GalpNAC-(1-PO3-), both linked via anomeric phosphodiester linkages. Also efforts towards the...

5/3,K/9 (Item 9 from file: 5) Links  
Fulltext available through: STIC Full Text Retrieval Options  
Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.  
15644135 Biosis No.: 200000362448  
Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom

Author: Borrow Ray (Reprint); Longworth Emma; Gray Stephen J; Kaczmarski Edward B  
Author Address: Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Nell Lane, West Didsbury, Manchester, M20 2LR, UK\*\*UK  
Journal: FEMS Immunology and Medical Microbiology 28 ( 3 ): p 189-191 July, 2000 2000  
Medium: print  
ISSN: 0928-8244  
Document Type: Article  
Record Type: Abstract  
Language: English  
Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom

Abstract: Meningococcal serogroup C conjugate (MCC) vaccines have been introduced in the UK to combat the rise in serogroup C meningococcal disease. Serogroup C meningococci may occur naturally expressing either O-acetylated (Oac+) or de-O-acetylated (Oac-) polysaccharide capsules. In a small study in the USA in the 1970s 15% of serogroup C meningococcal case isolates were reported to be Oac- though the prevalence of these Oac- isolates has not been recorded in the UK. This is of interest as the first MCC vaccines to be introduced are Oac+ and the potential impact of this on Oac- serogroup C isolates is unclear. Serogroup C isolates submitted to the Public Health Laboratory Service Meningococcal Reference Unit in January 1998 (n = 113) and January 1999 (n = 162) were investigated by dot blotting using monoclonals specific for Oac+ and Oac- serogroup C polysaccharides. This revealed 12% Oac- isolates for both January 1998 and January 1999. The proportion of fatal cases was found to be similar for both Oac- and Oac+, 14 and 9% for 1998 and 5

meningroupy.txt

and 3% for 1999, indicating that the pathogenic potential of these Oac- isolates is similar to Oac+. The acetylation status of serogroup C isolates needs to be monitored throughout and after the...

DESCRIPTORS:

Organisms: ...serogroup C meningococcus (Neisseriaceae...

Organisms: Parts Etc:

Diseases: de-O-acetylated serogroup C meningococci disease...

Mesh Terms:

Chemicals & Biochemicals: meningococcal serogroup C conjugate vaccines

5/3,K/10 (Item 10 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15517412 Biosis No.: 200000235725

Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine

Author: Borrow Ray (Reprint); Richmond Peter; Kaczmarek Edward B; Iverson Angela; Martin Sarah L; Findlow Jamie; Acuna Marisa; Longworth Emma; O'Connor Rachael; Paul John; Miller Elizabeth

Author Address: Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Nell Lane, Manchester, M20 2LR, UK\*\*UK

Journal: FEMS Immunology and Medical Microbiology 28 ( 1 ): p 79-85 May, 2000 2000

Medium: print

ISSN: 0928-8244

Document Type: Article

Record Type: Abstract

Language: English

Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine

Abstract: In the UK, a co-ordinated series of phase II studies is being undertaken with meningococcal serogroup C conjugate (MCC) vaccines. The use of meningococcal A/C polysaccharide (MACP) vaccines in control arms in young children has been avoided because... specific IgG ELISA and serum bactericidal assays (SBA) were performed using both de-O-acetylated (Oac-) and acetylated (Oac+) serogroup C antigen, the measurement of primarily high avidity antibody and using baby rabbit or...

DESCRIPTORS:

Diseases: meningococcal disease...

Mesh Terms: Meningococcal Infections (MeSH)

Chemicals & Biochemicals: ...meningococcal A/C polysaccharide vaccine

5/3,K/11 (Item 11 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

09600483 Biosis No.: 198987048374

MURINE IMMUNE RESPONSE TO THE NEISSERIA-MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE II. SPECIFICITY

Author: RUBINSTEIN L J (Reprint); STEIN K E

Author Address: DIV BACTERIAL PROD, CBER, FDA, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892, USA \*\*USA

Journal: Journal of Immunology 141 ( 12 ): p 4357-4362 1988

ISSN: 0022-1767



Document Type: Article

Record Type: Abstract

Language: ENGLISH

MURINE IMMUNE RESPONSE TO THE NEISSERIA-MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE II. SPECIFICITY

Abstract: ...further understanding the regulation of diversity and the development of protective immunity to the Neisseria meningitidis group C capsular polysaccharide (MCPS), we have generated and characterized, in detail, a panel of... ..reacted with MCPS alone. Seven of 15 reacted with a natural O-acetyl-negative variant (OAC-, strain MC19) polysaccharide as well as with MCPS. Five of these reacted as much as 3 logs better with OAC- than MCPS and the other two reacted better with MCPS than OAC-. One mAb appeared to be .alpha.(2.fwdarw.9)-linkage specific as it reacted not only with MCPS and OAC-, but also with the capsular polysaccharide of Escherichia coli K92, a polymer of sialic acid... ..and IgG isotypes and of both major specificities, MCPS-specific and those bindings MCPS and OAC-, were bactericidal for strain C11, whereas only those reactive with OAC- were able to kill strain MC19.

5/3,K/12 (Item 12 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

09600482 Biosis No.: 198987048373

MURINE IMMUNE RESPONSE TO THE NEISSERIA-MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE I. ONTOGENY

Author: RUBINSTEIN L J (Reprint); STEIN K E

Author Address: DIV BACTERIAL PROD, CBER, FDA, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892, USA \*\*USA

Journal: Journal of Immunology 141 ( 12 ): p 4352-4356 1988

ISSN: 0022-1767

Document Type: Article

Record Type: Abstract

Language: ENGLISH

MURINE IMMUNE RESPONSE TO THE NEISSERIA-MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE I. ONTOGENY

Abstract: ...pathogens. We have examined the BALB/c murine response to the capsular polysaccharide of Neisseria meningitidis group C (MCPS), a homopolymer of .alpha.(2.fwdarw.9) sialic acid, as a model... ..include antibody titers to both MCPS as well as a natural O-acetyl-negative variant (OAC-). The preimmune anti-OAC-antibodies, in contrast to anti-MCPS, were restricted to the IgM class, whereas after immunization with MCPS both IgM and low titers of IgG3 antibodies to OAC- were produced. These studies demonstrate that the BALB/c mouse strain shows a markedly similar...

5/3,K/13 (Item 13 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

08082881 Biosis No.: 198681046772

STRUCTURAL DETERMINATION OF THE GROUP K CAPSULAR POLYSACCHARIDE OF NEISSERIA-MENINGITIDIS A 2-DIMENSIONAL NMR ANALYSIS

Author: MICHON F (Reprint); BRISSON J R; ROY R; JENNINGS H J; ASHTON F E

Author Address: DIV BIOLOGICAL SCI, NATIONAL RESEARCH COUNCIL OF CANADA, OTTAWA, ONT, CANADA K1A 0R6\*\*CANADA

Journal: Canadian Journal of Chemistry 63 ( 10 ): p 2781-2786 1985

ISSN: 0008-4042

meningroupy.txt

Document Type: Article  
Record Type: Abstract  
Language: ENGLISH  
STRUCTURAL DETERMINATION OF THE GROUP K CAPSULAR POLYSACCHARIDE OF  
NEISSERIA-MENINGITIDIS A 2-DIMENSIONAL NMR ANALYSIS

Abstract: The capsular polysaccharide antigen to *N. meningitidis* group K was isolated by Cetavlon precipitation and purified by ion-exchange chromatography. The structure... is composed of the following repeating unit: -4).beta.-D-ManpNAC(1.fwdarw. 3) [4-OAc].beta.-D-ManpNAC(1.fwdarw.. Except for the one-bond couplings between their anomeric carbons...

5/3,K/14 (Item 14 from file: 5) Links  
Fulltext available through: STIC Full Text Retrieval Options  
Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.  
08063120 Biosis No.: 198681027011  
STRUCTURAL DETERMINATION OF THE CAPSULAR POLYSACCHARIDE OF NEISSERIA- MENINGITIDIS  
GROUP I A TWO-DIMENSIONAL NMR ANALYSIS

Author: MICHON F (Reprint); BRISSON J R; ROY R; ASHTON F E; JENNINGS H J  
Author Address: DIV BIOL SCI, NATL RES COUNCIL CAN, OTTAWA, ONTARIO K1A 0R6,  
CAN\*\*CANADA  
Journal: Biochemistry 24 ( 20 ): p 5592-5598 1985  
ISSN: 0006-2960  
Document Type: Article  
Record Type: Abstract  
Language: ENGLISH  
STRUCTURAL DETERMINATION OF THE CAPSULAR POLYSACCHARIDE OF NEISSERIA- MENINGITIDIS  
GROUP I A TWO-DIMENSIONAL NMR ANALYSIS

Abstract: The capsular polysaccharide antigen of *Neisseria meningitidis* group I was isolated by Cetavlon precipitation and purified by ion-exchange chromatography. The structure... is composed of the repeating unit .fwdarw. 4).alpha.-L-GulpNAC(1.fwdarw. 3)[4-OAc].beta.-D-ManpNAC (.fwdarw. in which the former residue adopts the 4C1 (L) conformation and...

5/3,K/15 (Item 1 from file: 24) Links  
Fulltext available through: STIC Full Text Retrieval Options  
CSA Life Sciences Abstracts  
(c) 2009 CSA. All rights reserved.  
0002593285 IP Accession No: 5954117  
A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for  
detection of enteroviral RNA

Mohamed, N; Elfaitouri, A; Fohlman, J; Friman, G; Blomberg, J\* Section of Virology,  
Department of Medical Sciences, Uppsala University, Uppsala 751 85, Sweden,  
[mailto:jonas.blomberg@medsci.uu.se]  
Journal of Clinical Virology, v 30, n 2, p 150-156, June 2004  
Publication Date: 2004  
Publisher: Elsevier B.V.

Document Type: Journal Article  
Record Type: Abstract  
Language: English  
Summary Language: English  
ISSN: 1386-6532  
File Segment: Industrial & Applied Microbiology Abstracts (Microbiology A); Virology  
& AIDS Abstracts

Abstract:

...The method was evaluated with serial dilutions of EV, 62 cerebrospinal fluid (CSF) specimens from meningitis patients, and the third and fourth European Union Concerted Action Enterovirus Proficiency Panels. A commercial... from the 5 non-coding region as well as recombinant *Thermus thermophilus* polymerase (rth), Mn(OAc)2 and thermolabile UNG concentrations. Of 62 CSF samples from cases of meningitis submitted for QPCR testing, 34 (76%) and 21 (47%) were positive by QPCR and a...

5/3,K/16 (Item 2 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts

(c) 2009 CSA. All rights reserved.

0000429006 IP Accession No: 1116875

Evaluation of two tetravalent (ACYW sub(135)) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Peltola, H; Safary, A; Kaeyhty, H; Karanko, V; Andre, FE Natl. Public Health Inst., Mannerheimintie 166, SF-00280 Helsinki 28, Finland

Pediatrics, v 76, n 1, p 91-96, 1985

Addl. Source Info: Pediatrics, vol. 76, no. 1, pp. 91-96, 1985

Publication Date: 1985

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English

ISSN: 0031-4005

File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts

Evaluation of two tetravalent (ACYW sub(135)) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative...

Abstract:

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W sub(135) meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAc super(-)) and 78 the acetylated group C polysaccharide C(OAc super(+)) together with group A, Y, and W sub(135) polysaccharides. All polysaccharides, at a... responses were better in the older infants. The authors conclude that tetravalent (ACYW sub(135)) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations...

Descriptors: vaccines; immunogenicity; children; man; Neisseria meningitidis

Identifiers:

5/3,K/17 (Item 1 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

15545386 Genuine Article#: 082DX No. References: 55

Attenuation of penicillin resistance in a peptidoglycan O-acetyl transferase mutant of *Streptococcus pneumoniae*

Author: Crisostomo MI; Vollmer W; Kharat AS; Inhulsen S; Gehre F; Buckenmaier S;

Tomasz A (REPRINT)

Corporate Source: Rockefeller Univ, Microbiol Lab, New York/NY/10021 (REPRINT);

meninggroupy.txt

Rockefeller Univ, Microbiol Lab, New York//NY/10021; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Genet Mol Lab, Oeiras//Portugal//; Univ Tubingen, Proteom Cent Tubingen, Tubingen//Germany// ( tomasz@rockefeller.edu )  
Journal: MOLECULAR MICROBIOLOGY, 2006, V 61, N6 ( SEP ), P 1497-1509  
ISSN: 0950-382X Publication date: 20060900  
Publisher: BLACKWELL PUBLISHING, 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND  
Language: English Document type: ARTICLE ( ABSTRACT AVAILABLE )  
Identifiers-- ...BETA-LACTAM RESISTANCE; BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS; NEISSERIA-MENINGITIDIS; CELL-WALL; MURMN OPERON; IN-VITRO; GENETIC-TRANSFORMATION; METHICILLIN RESISTANCE; ANTIBIOTIC-RESISTANCE  
Research Fronts:

5/3,K/18 (Item 2 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options  
SciSearch(R) Cited Ref Sci  
(c) 2009 The Thomson Corp. All rights reserved.  
15515110 Genuine Article#: 080LV No. References: 54  
Separate pathways for O acetylation of polymeric and monomeric sialic acids and identification of sialyl O-acetyl esterase in Escherichia coli K1

Author: Steenbergen SM; Lee YC; Vann WF; Vionnet J; Wright LF; Vimr ER (REPRINT)  
Corporate Source: Univ Illinois, Dept Pathobiol, Lab Sialobiol, 2522 VMSB, 2001 S Lincoln Ave/ Urbana//IL/61802 (REPRINT); Univ Illinois, Dept Pathobiol, Lab Sialobiol, Urbana//IL/61802; Univ Illinois, Dept Pathobiol, Lab Sialobiol & Comparat Metabolom, Urbana//IL/61802; Dong A Univ, Dept Biotechnol, Pusan//South Korea//; US FDA, Ctr Biol Evaluat & Res, Bethesda//MD/20014; Univ Rochester, Dept Microbiol & Immunol, Rochester//NY/14627 ( ervimr@uiuc.edu )  
Journal: JOURNAL OF BACTERIOLOGY, 2006, V 188, N17 ( SEP ), P 6195-6206  
ISSN: 0021-9193 Publication date: 20060900  
Publisher: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA  
Language: English Document type: ARTICLE ( ABSTRACT AVAILABLE )  
Identifiers-- ...MOBILE CONTINGENCY LOCUS; MENINGITIDIS GROUP-B; CAPSULAR POLYSACCHARIDE; GENETIC-ANALYSIS; FORM VARIATION; METABOLISM; SYNTHETASE; MUTATIONS; MECHANISM; DISEASE  
Research Fronts:

5/3,K/19 (Item 3 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options  
SciSearch(R) Cited Ref Sci  
(c) 2009 The Thomson Corp. All rights reserved.  
12448577 Genuine Article#: 765UF No. References: 24  
Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD)

Author: Kao G; Tsai CM (REPRINT)  
Corporate Source: US FDA, Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Off Vaccine Res, 1401 Rockville Pike HFM-428/Rockville//MD/20852 (REPRINT); US FDA, Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Off Vaccine Res, Rockville//MD/20852  
Journal: VACCINE, 2004, V 22, N3-4 ( JAN 2 ), P 335-344  
ISSN: 0264-410X Publication date: 20040102  
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND  
Language: English Document type: ARTICLE ( ABSTRACT AVAILABLE )  
Abstract: The O-acetyl groups in meningococcal A and typhoid Vi polysaccharides (PSS) are functional immunogenic epitopes in humans. To quantify and... groups in the PSS after these groups were hydrolyzed into anions. The O-acetylation in meningococcal A, C, Y and W-135, pneumococcal 9V and 18C and typhoid Vi PSS were...  
...The HPAEC method can quantify the O-acetyl content in 0.2 mug of the meningococcal C PS and has a sensitivity at least 10 times higher than that of

meningroupy.txt

the..:

Identifiers-- ...PULSED-AMPEROMETRIC DETECTION; NUCLEAR-MAGNETIC-RESONANCE;  
MENINGITIDIS SEROGROUP-A; PNEUMONIAE TYPE 9V; NEISSERIA- MENINGITIDIS; CAPSULAR  
POLYSACCHARIDE; STRUCTURAL DETERMINATION; GROUP-B; ANTIGENS; RESPONSES

5/3,K/20 (Item 4 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

12261722 Genuine Article#: 748EE No. References: 26

The structure of the glycopeptides from the fish pathogen *Flavobacterium columnare*

Author: Vinogradov E (REPRINT) ; Perry MB; Kay WW  
Corporate Source: Natl Res Council Canada,Inst Biol Sci,100 Sussex Dr/Ottawa/ON K1A  
0R6/Canada/ (REPRINT); Natl Res Council Canada,Inst Biol Sci,Ottawa/ON K1A  
0R6/Canada/; Univ Victoria,Dept Bacteriol & Biochem,Victoria/BC V8W 2T2/Canada/  
Journal: CARBOHYDRATE RESEARCH , 2003 , V 338 , N23 ( NOV 14 ) , P 2653-2658  
ISSN: 0008-6215 Publication date: 20031114  
Publisher: ELSEVIER SCI LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5  
1GB, OXON, ENGLAND  
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )  
Abstract: ...alpha-glCA-(1-->2)-alpha-Man-(1-O-Ser \4 2\\3 2\ OMe AcO OAc OMe

where all monosaccharides have the D-configuration except for  
2-O-methyl-L-rhamnose...

Identifiers-- ...CAMPYLOBACTER-JEJUNI; LINKED GLYCAN; GLYCOSYLATION; GLYCOPROTEIN;  
PILIN; FLAGELLIN; PROTEIN; MENINGOSEPTICUM; IDENTIFICATION; RESOLUTION

5/3,K/21 (Item 5 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

11206251 Genuine Article#: 619YI No. References: 44

Use and validation of NMR assays for the identity and O-acetyl content of capsular  
polysaccharides from *Neisseria meningitidis* used in vaccine manufacture

Author: Jones C (REPRINT) ; Lemercinier X  
Corporate Source: Natl Inst Biol Stand & Controls,Lab Mol Struct,Blanche Lane S  
Mimms/Potters Bar EN6 3QG/Herts/England/ (REPRINT); Natl Inst Biol Stand &  
Controls,Lab Mol Struct,Potters Bar EN6 3QG/Herts/England/  
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS , 2002 , V 30 , N4 ( NOV  
7 ) , P 1233-1247  
ISSN: 0731-7085 Publication date: 20021107  
Publisher: PERGAMON-ELSEVIER SCIENCE LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON,  
OXFORD OX5 1GB, ENGLAND  
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )  
...of NMR assays for the identity and O-acetyl content of capsular polysaccharides  
from *Neisseria meningitidis* used in vaccine manufacture

Abstract: ...nuclear magnetic resonance) spectroscopic assay for the identity of the  
capsular polysaccharides (CPSS) from *Neisseria meningitidis* Groups A, C, W135 and Y  
used in vaccine manufacture, and to determine the proportion... ..and quantitation  
of the O-acetyl content are key control parameters for these vaccines. The  
meningococcal CPSS have variable levels of O-acetylation, present at multiple sites  
in the repeat unit...

Identifiers-- ...GROUP-B POLYSACCHARIDE; NUCLEAR MAGNETIC-RESONANCE; CONJUGATE  
VACCINE; SEROGROUP-C; MENINGOCOCCAL POLYSACCHARIDE; BACTERIAL POLYSACCHARIDES;  
STRUCTURAL DETERMINATION; IMMUNOGENICITY; ANTIGENS; EPITOPE

5/3,K/22 (Item 6 from file: 34) Links

meningroupy.txt

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

03621848 Genuine Article#: PT237 No. References: 23

STRUCTURE OF THE O-16 POLYSACCHARIDE FROM ESCHERICHIA-COLI O-16-K1 - AN NMR INVESTIGATION

Author: JANN B; SHASHKOV AS; KOCHANOWSKI H; JANN K  
Corporate Source: MAX PLANCK INST IMMUNBIOL, STUBEWEG 51/D-79108 FREIBURG//GERMANY/;

MAX PLANCK INST IMMUNBIOL/D-79108 FREIBURG//GERMANY/

Journal: CARBOHYDRATE RESEARCH, 1994, V 264, N2 ( NOV 15 ), P 305-311

ISSN: 0008-6215

Language: ENGLISH Document Type: ARTICLE ( Abstract Available )

Abstract: ...alpha-L-Rhap-(1 --> 3)-alpha-D-GlcpNAC-(1 --> 2)-beta-D-Galf-(1 --> 2 \ OAC

Identifiers--

Research Fronts: 92-0159 001 (CAPSULAR POLYSACCHARIDE; ESCHERICHIA-COLI MENINGITIS;

STRUCTURAL ELUCIDATION; SALMONELLA O-8 ANTIGEN)

92-0744 001 (STRUCTURAL ELUCIDATION; H-1 NUCLEAR-MAGNETIC...

Cited References:

5/3,K/23 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0072801464 EMBASE No: 1985206880

Evaluation of two tetravalent (ACYW SUB 135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides

Peltola H.; Safary A.; Kayhty H.; et-al

Children's Hospital, University of Helsinki, Helsinki, Finland

Corresp. Author/Affil: : Children's Hospital, University of Helsinki, Helsinki, Finland

Pediatrics ( PEDIATRICS ) ( United States ) October 31, 1985, 76/1 (91-96)

CODEN: PEDIA ISSN: 0031-4005

Document Type: Journal Record Type: Abstract

Language: English

Evaluation of two tetravalent (ACYW SUB 135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative...

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W SUB 135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAC SUP -) and 78 the acetylated group C polysaccharide C(OAC SUP +) together with group A, Y, and W SUB 135 polysaccharides. All polysaccharides, at a... 38.5(deg)C (101.3(deg)F). We conclude that tetravalent (ACYW SUB 135) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations...

Drug Descriptors:

\* bacterial antigen; \*meningococcus vaccine; \*polysaccharide

5/3,K/24 (Item 1 from file: 155) Links

Fulltext available through: STIC Full Text Retrieval Options

MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

07649693 PMID: 3925430

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small

Page 22

meningroupy.txt

children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Peltola H; Safary A; Kayhty H; Karanko V; Andre F E  
Pediatrics ( UNITED STATES ) Jul 1985 , 76 (1) p91-6 , ISSN: 0031-4005--Print  
Journal Code: 0376422  
Publishing Model Print  
Document type: Clinical Trial; Comparative Study; Journal Article; Randomized  
Controlled Trial  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed  
Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small  
children: a clinical study comparing immunogenicity of O-acetyl-negative...

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... ..first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAC-) and 78 the acetylated group C polysaccharide C(OAC+) together with group A, Y, and W135 polysaccharides. All polysaccharides, at a dose of 30... ..fever exceeding 38.5 degrees C (101.3 degrees F). We conclude that tetravalent (ACYW135) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations... (

Descriptors: \*Bacterial Vaccines--therapeutic use--TU; \*Meningococcal Infections--prevention and control--PC; \*Neisseria meningitidis--immunology--IM ;  
...Antibodies, Bacterial--analysis--AN; Bacterial Vaccines--immunology--IM;  
Double-Blind Method; Humans; Immunization, Secondary; Infant; Meningococcal  
Vaccines; Time Factors

Named Person:

Chemical Name: Antibodies, Bacterial; Bacterial Vaccines; Meningococcal Vaccines

5/3,k/25 (Item 1 from file: 162) Links

Fulltext available through: STIC Full Text Retrieval Options

Global Health

(c) 2009 CAB International. All rights reserved.

0004998767 CAB Accession Number: 20043089561

A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for detection of enteroviral RNA.

Nahla Mohamed; Amal Elfaitouri; Fohlman, J.; Friman, G.; Blomberg, J.

Author email address: jonas.blomberg@medsci.uu.se

Section of Virology, Department of Medical Sciences, Uppsala University, Uppsala 751 85, Sweden.

Journal of Clinical Virology vol. 30 ( 2 ): p.150-156

Publication Year: 2004

ISSN: 1386-6532

Digital Object Identifier: 10.1016/j.jcv.2003.08.016

Publisher: Elsevier Science Ltd Oxford, UK

Language: English Record Type: Abstract

Document Type: Journal article

... The method was evaluated with serial dilutions of EV, 62 cerebrospinal fluid (CSF) specimens from meningitis patients, and the third and fourth European Union Concerted Action Enterovirus Proficiency Panels. A commercial... ..the 5prime non-coding region as well as recombinant Thermophilus polymerase (r Tth ), Mn(OAC ) SUB 2 and thermolabile UNG concentrations. Of 62 CSF samples from cases of meningitis submitted for QPCR testing, 34 (76%) and 21 (47%) were positive by QPCR and a...

Descriptors: ...viral meningitis

Identifiers:

5/3,K/26 (Item 1 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 6532822

Title: In vivo determination of *Neisseria meningitidis* serogroup A capsular polysaccharide by whole cell high-resolution magic angle spinning NMR spectroscopy

Document Type: Journal Record Type: Abstract

Author: Gudlavalletti, Seshu K.; Szymanski, Christine M.; Jarrell, Harold C.;

Stephens, David S.

Citation: Carbohydr. Res. (2006) Series: SIN341-4, 557 - 562 CODEN: CRBRAT Language: English

Abstract Language: English

Title: In vivo determination of *Neisseria meningitidis* serogroup A capsular polysaccharide by whole cell high-resolution magic angle spinning NMR spectroscopy

Document Type:

Abstract: High resolution-magic angle spinning (HRMAS) NMR spectroscopy was applied to serogroup A *Neisseria meningitidis* (NMA) to determine precise structures of capsular polysaccharide (CPS) expressed on the meningococcal surface. Both the O-acetylated ( OAc) NMA parent and a *mynC::aphA3* OAc-mutant demonstrated characteristic CPS-derived NMR signals indicating cell-surface expression of CPS, but only...

Abstract Language:

Keywords: *Neisseria meningitidis*; HRMAS NMR spectroscopy; O-acetylation; capsular polysaccharide; meningococci; vaccine development

5/3,K/27 (Item 2 from file: 393) Links

Beilstein Database - Abstracts

(c) 2008 Beilstein GmbH. All rights reserved.

Beilstein Abstract Id: 5683341

Title: Structural determination of the group K capsular polysaccharide of *Neisseria meningitidis*: a 2D-NMR analysis

Document Type: Journal Record Type: Abstract

Author: Michon, Francis; Brisson, Jean Robert; Roy, Rene; Jennings, Harold J.;

Ashton, Fraser E.

Citation: Can.J.Chem. (1985) Series: 63, 2781-2786 CODEN: CJCHAG Language: English

Abstract Language: English

Title: Structural determination of the group K capsular polysaccharide of *Neisseria meningitidis*: a 2D-NMR analysis

Document Type:

Abstract: The capsular polysaccharide antigen of *Neisseria meningitidis* group K was isolated by Cetavlon precipitation and purified by ion-exchange chromatography. The structure... polysaccharide is composed of the following repeating unit: -4) beta -D-ManpNACA(1-3) (4-OAc ) beta -D-ManpNACA(1-). Except for the one-bond couplings between their anomeric carbons and ...

Abstract Language:

5/3,K/28 (Item 1 from file: 35) Links

Dissertation Abs Online

(c) 2008 ProQuest Info&Learning. All rights reserved.

02187252 ORDER NO: AADAA-I3238518

Discovery, characterization and pathologic relevance of sialic acid O-acetylation in group B *Streptococcus*

Author: Lewis, Amanda L.

Degree: Ph.D.

Year: 2006

Corporate Source/Institution: University of California, San Diego ( 0033 )

Source: Volume 6710B of Dissertations Abstracts International.

PAGE 5540 . 152 PAGES



ISBN: 978-0-542-92540-5

...Group B *Streptococcus* (GBS) is the leading cause of human neonatal sepsis and meningitis. The sialylated GBS capsular polysaccharide (CPS) of GBS is a major virulence factor and the... ..Ac was present on all tested GBS strains and fell into two phenotypic categories: "low-OAC" (<5%) and "high-OAC" (>20%). Sequencing and allelic replacement techniques show that a single *neuB* polymorphism contributes functionally to... ..50 type III) indicates that while the type Ia strains are almost exclusively the low-OAC phenotype, all the type III strains exhibit the high-OAC phenotype. Interestingly, *neuB* is common among bacterial *Sia* biosynthetic gene clusters. Phylogenetic analyses...

5/3,K/29 (Item 1 from file: 135) Links  
NewsRx Weekly Reports  
(c) 2009 NewsRx. All rights reserved.

0000735853 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Center for Biologics Evaluation and Research details research in tetanus vaccines

Biotech Business Week, January 28, 2008, p.2725

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English  
RECORD TYPE: FULLTEXT

Word Count:  
394

TEXT: 8 JAN 28 - (& NewsRx.net) -- Current study results from the report, "Comparison of *Neisseria meningitidis* serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non...

...also ). "Polysaccharide (PS) and tetanus toxoid (TT) protein conjugate vaccines were prepared using O-acetylated (OAC+), O-acetyl negative (OAC(-)) and chemically de-O-acetylated (de-OAC) meningococcal W135 PS. The PSs were activated by periodate oxidation and coupled to hydrazine derivatized TT...

...exchange chromatography of acid hydrolysates of periodate activated W135 PSs, showed that galactose residues in OAC+ PS were more sensitive to the periodate oxidation step than they were in the OAC(-) PS or de-OAC PS. Mouse antisera against OAC(-)-TT conjugate vaccines recognized both OAC(-) and OAC+ PS by ELISAs and had high bactericidal titers against both OAC+ and OAC(-) W135 strains. Purified high molecular weight (HMW) conjugates showed higher PS to protein ratios in OAC(-)-TT(HMW) and de-OAC-TT(HMW) indicating better conjugation efficiency than OAC+ -TT(HMW) conjugate. Antisera against the HMW fractions gave higher bactericidal titers than antisera against unfractionated conjugates. Inhibition ELISAs indicated that OAC(-) and OAC+ HMW conjugates induced antibodies that bound both OAC+ and OAC(-) PS. Thus, for W135, PS O-acetylation does not contribute a dominant immunogenic epitope," wrote S.K. Gudlavalleti and colleagues, Center for Biologics Evaluation and Research. The researchers concluded: "The OAC(-) PS may be a good starting material for preparing W135 PS-TT conjugate vaccines using... Vaccine (Comparison of *Neisseria meningitidis* serogroup W135

meninggroupy.txt  
polysaccharide-tetanus toxoid conjugate vaccines made by periodate  
activation of O-acetylated, non...

...Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: United States,  
Bethesda, Tetanus Vaccines, Biologics, Biotechnology, Chromatography,  
Meningococcal, Tetanus, Vaccines. This article was prepared by  
Biotech Business Week editors from staff and other...

DESCRIPTORS: United States; Bethesda; Tetanus Vaccines; Biologics;  
Biotechnology; Chromatography; Meningococcal;  
Tetanus; VaccinesAll News; Professional News

5/3,K/30 (Item 2 from file: 135) Links  
NewsRx Weekly Reports  
(c) 2009 NewsRx. All rights reserved.

0000713419 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Scientists at Center for Biologics Evaluation and Research target tetanus  
vaccines

Biotech Business Week, December 24, 2007, p.1598

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English  
RECORD TYPE: FULLTEXT

Word Count:  
397

TEXT: 7 DEC 24 - ( & NewsRx.net) -- Scientists discuss in 'Comparison  
of Neisseria meningitidis serogroup w135 polysaccharide-tetanus  
toxoid conjugate vaccines made by periodate activation of O-acetylated, non  
...

...States, "Polysaccharide (PS) and tetanus toxoid (TT) protein conjugate  
vaccines were prepared using O-acetylated (OAC+), O-acetyl negative  
(OAC(-)) and chemically de-O-acetylated (de-OAC)  
meningococcal w135 PS. The PSS were activated by periodate oxidation  
and coupled to hydrazine derivatized TT...

...exchange chromatography of acid hydrolysates of periodate activated w135  
PSS, showed that galactose residues in OAC+ PS were more sensitive  
to the periodate oxidation step than they were in the OAC(-) PS or  
de-OAC PS. Mouse antisera against OAC(-)-TT conjugate  
vaccines recognized both OAC(-) and OAC+ PS by ELISAs and had  
high bactericidal titers against both OAC+ and OAC(-) w135  
strains. Purified high molecular weight (HMW) conjugates showed higher PS  
to protein ratios in OAC(-)-TT(HMW) and de-OAC-TT(HMW)  
indicating better conjugation efficiency than OAC+-TT(HMW)  
conjugate. Antisera against the HMW fractions gave higher bactericidal  
titers than antisera against unfractionated conjugates. Inhibition ELISAs  
indicated that OAC(-) and OAC+ HMW conjugates induced  
antibodies that bound both OAC+ and OAC(-) PS. Thus, for  
w135, PS O-acetylation does not contribute a dominant immunogenic epitope,"  
wrote S.K. Gudlavalleti and colleagues, Center for Biologics Evaluation and  
Research. The researchers concluded: "The OAC(-) PS may be a good

meningroupY.txt  
starting material for preparing W135 PS-TT conjugate vaccines using...  
Vaccine (Comparison of Neisseria meningitidis serogroup W135  
polysaccharide-tetanus toxoid conjugate vaccines made by periodate  
activation of O-acetylated, non...

...Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: United States,  
Bethesda, Tetanus Vaccines, Biologics, Biotechnology, Chromatography,  
Meningococcal, Tetanus, Vaccines. This article was prepared by  
Biotech Business Week editors from staff and other...

DESCRIPTORS: United States; Bethesda; Tetanus Vaccines; Biologics;  
Biotechnology; Chromatography; Meningococcal;  
Tetanus; VaccinesAll News; Professional News

5/3,K/31 (Item 3 from file: 135) Links  
NewsRx Weekly Reports  
(c) 2009 NewsRx. All rights reserved.

0000152297 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Responses to meningococcal group C conjugate vaccines determined

Immunotherapy Weekly, August 11, 2004, p.159

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English  
RECORD TYPE: FULLTEXT

Word Count:  
352

Responses to meningococcal group C conjugate vaccines determined

...TEXT: have performed a surface plasmon resonance analysis of  
antipolysaccharide antibody specificity to determine responses to  
meningococcal group C conjugate vaccines and bacteria.  
"Antibody responses to polysaccharides (PS), such as Neisseria  
meningitidis group C PS (MCPS), are characterized as being thymus  
independent and are restricted with regard...  
... plasmon resonance approach to evaluate antibody responses to MCPS  
conjugate vaccines, including either O-acetylated (OAC+) or  
de-O-acetylated (OAC-) forms of the PS," said Pablo A. Garcia-Ojeda  
and collaborators at the National Institute...

...that sera from mice immunized with conjugate vaccines contain antibodies  
that bind more effectively to OAC+ and OAC- MCPS than sera  
from mice immunized with fixed bacteria."

The researchers concluded, "The data suggest...

...study in Infection and Immunity (Surface plasmon resonance analysis of  
antipolysaccharide antibody specificity: Responses to meningococcal  
group C conjugate vaccines and bacteria. Infect Immunology,  
2004;72(6):3451-3460).

Additional information...

...20036-2904, USA.

The information in this article comes under the major subject areas of  
Meningococcal Vaccine, Bacteriology, Vaccine Development,

meningroupy.txt  
Immunology, Immunotherapy, and Meningitis.

This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2004...

SUBJECT HEADING: Meningococcal Vaccine

5/3,K/32 (Item 1 from file: 357) Links  
Derwent Biotech Res.

(C) 2008 Thomson Reuters. All rights reserved.

0441686 DBA Accession No.: 2007-28544 PATENT

New 1,2,4-triazol-1-yl bisphenyl derivatives useful for treatment of e.g. cancer, autoimmune disorders, or inflammatory disorders employing 1,2,4-triazol-1-yl bisphenyl derivative, an aromatase-inhibitor, sulfatase-inhibitor, for use in treating cancer, inflammation, fever, anorexia, HIV virus infection, autoimmune disease, cerebral ischemia, osteoarthritis, rheumatoid arthritis, asthma, multiple sclerosis, Alzheimer disease, atherosclerosis, stroke, Crohn disease, psoriasis, hemophilia

Author: WOO L W L; JACKSON T; PUROHIT A; REED M J; POTTER B V L

Patent Assignee: STERIX LTD 2007

Patent Number: WO 200768905 Patent Date: 20070621 WPI Accession No.: 2007-859773  
( 200779 )

Priority Application Number: GB 200525323 Application Date: 20051213

National Application Number: WO 2006GB4630 Application Date: 20061212

Language: English

Abstract: ...anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine; angiogenesis, metastases, cerebral ischemia, ischemic heart disease, osteoarthritis, rheumatoid arthritis, asthma, multiple sclerosis, neurodegeneration....hydroxyphenylboronic acid (.174 g), K<sub>2</sub>CO<sub>3</sub> (0.29 g), tetrabutylammonium bromide (TBAB) (0.279 g), Pd(OAc)<sub>2</sub> (0.005 - 0.006 g) in ethano (1.5 ml) and water (3.5...  
E.C. Numbers:

5/3,K/33 (Item 2 from file: 357) Links  
Derwent Biotech Res.

(C) 2008 Thomson Reuters. All rights reserved.

0423716 DBA Accession No.: 2007-09654 PATENT

New composition comprising conjugated capsular saccharides from Streptococcus pneumoniae and Neisseria meningitidis serogroup C, and an inactivated poliovirus antigen, useful for raising an immune response Streptococcus pneumoniae and Neisseria meningitidis serogroup-C conjugated capsular saccharide and inactivated polio virus antigen for attenuated vaccine and immune response induction

Author: BORKOWSKI A

Patent Assignee: NOVARTIS VACCINES and DIAGNOSTICS INC 2007

Patent Number: WO 200726249 Patent Date: 20070308 WPI Accession No.: 2007-255173  
( 200725 )

Priority Application Number: US 750894 Application Date: 20051216

National Application Number: WO 2006IB2861 Application Date: 20060901

Language: English

New composition comprising conjugated capsular saccharides from Streptococcus pneumoniae and Neisseria meningitidis serogroup C, and an inactivated poliovirus antigen, useful for raising an immune response Streptococcus pneumoniae and Neisseria meningitidis serogroup-C conjugated capsular saccharide and inactivated polio virus antigen for attenuated vaccine and immune...

Abstract: ...composition comprising a conjugated capsular saccharide from Streptococcus pneumoniae, a conjugated capsular saccharide from Neisseria meningitidis serogroup C, and an inactivated poliovirus antigen, where the

# meningroupy.txt

composition is in aqueous form, is.....from *S. pneumoniae*, and the second immunogenic component comprises a conjugated capsular saccharide from *N. meningitidis* serogroup C; (2) a method of raising an immune response in a patient; and (3).....a conjugated capsular saccharide from *S. pneumoniae*, and (ii) a conjugated capsular saccharide from *N. meningitidis* serogroup C, in the manufacture of a medicament for immunizing a patient. BIOTECHNOLOGY - Preferred Composition... ..includes an aluminum hydroxide adjuvant and an aluminum phosphate adjuvant. The capsular saccharide from *N. meningitidis* serogroup C is OAC+. The first or the second component does not include an aluminum phosphate adjuvant. The *N. meningitidis* serogroup C conjugate is not or is adsorbed to an aluminum phosphate adjuvant. The capsular saccharide from *N. meningitidis* serogroup C is in lyophilized form. The first or second component includes one or more... ..ID NO: 1). A capsular saccharide from *S. pneumoniae* and a capsular saccharide from *N. meningitidis* serogroup C are each conjugated to the same carrier protein, where the same carrier protein... ..conjugate has a saccharide:protein ratio (w/w) of 1:10 - 10:1. The *N. meningitidis* conjugate has a saccharide:protein ratio (w/w) of 1:10 - 10:1. The composition... ..composition comprises a conjugated capsular saccharide from *S. pneumoniae*, a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, and a hepatitis B virus surface antigen. A kit comprises at least a... ..components comprises: a conjugated capsular saccharide from *S. pneumoniae*, a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, or a hepatitis B virus surface antigen. An immunogenic composition comprises a conjugated capsular saccharide from *S. pneumoniae*, a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, and inactivated poliovirus antigen. A kit comprises at least a first immunogenic component... ..components comprises: a conjugated capsular saccharide from *S. pneumoniae*, a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, or inactivated poliovirus antigen. A kit comprises a first immunogenic component and a... ..pertussis antigen; and (ii) the second immunogenic component comprises a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, in lyophilized form. A kit comprises a first immunogenic component and a second immunogenic component, where: (i) the first immunogenic component comprises a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C; and (ii) the second immunogenic component comprises an acellular *B. pertussis* antigen and... ..immunogenic component, where: (i) the first immunogenic component comprises a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C; (ii) the second immunogenic component comprises an acellular *B. pertussis* antigen and/or... ..third component, where: (i) the first immunogenic component comprises a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, but does not include an aluminum phosphate adjuvant; (ii) the second immunogenic component... ..capsular saccharide from *S. pneumoniae*. An immunogenic composition comprises a conjugated capsular saccharide from a OAC+ strain of *N. meningitidis* serogroup C, an acellular *B. pertussis* antigen and an inactivated poliovirus antigen. Preferred Method: Raising... ..of a conjugated capsular saccharide from *S. pneumoniae*, and the conjugated capsular saccharide from *N. meningitidis* serogroup C, are useful in manufacturing a medicament for immunizing a patient (all claimed). The composition is useful for reducing or preventing diseases, e.g. bacterial meningitis, including meningococcal meningitis, pneumococcal meningitis and Hib meningitis; viral hepatitis, including HBV and HAV infections; diphtheria; tetanus, or lockjaw; whooping cough, or pertussis; and/or poliomyelitis. ADMINISTRATION - The *N. meningitidis* conjugate is present at 1-20 micrograms (measured as saccharide) per dose. The *S. pneumoniae*...

E.C. Numbers:  
 Descriptors: *Streptococcus pneumoniae*, *Neisseria meningitidis* serogroup-C conjugated capsular saccharide, inactivated polio virus antigen, immunization in human patient, aluminum hydroxide... ..polysorbate, *Haemophilus influenzae* tetanus toxoid, protein D carrier protein, appl. attenuated vaccine, immune response induction, meningococcal meningitis, pneumococcal meningitis, Hib meningitis; viral hepatitis, HBV, HAV infection, diphtheria, tetanus, lockjaw, whooping cough, pertussis, poliomyelitis therapy, prevention bacterium...

Beilstein Database - Reactions

(c) 2008 Beilstein GmbH. All rights reserved.

Reaction Id: 839504

## Reactants

BN=96671 tetra- O -acetyl- alpha -D-galactopyranosyl bromide

## Products

BN=90782 tri- O -acetyl-2,6-anhydro-5-deoxy-D- arabino -hex-5-enitol

No. of Reaction Details: 18

No. of References: 19

## Reaction Details

...Ref. 6)

Classification: Preparation

Yield: 98 percent (BN=90782)

Reagent: Na2EDTA\*2H2O, Cr(OAc)2\*H2O

Solvent: H2O ethyl acetate

Time: 18 hour(s)

Conditions: Ambient temperature (Ref... ...16)

Classification: Preparation

Yield: 97 percent (BN=90782)

Reagent: Na2EDTA\*H2O (Cr(OAc)2\*H2O)2

Solvent: H2O ethyl acetate

Time: 18 hour(s)

ph: 5.0...

## References

...Carbohydrate-Protein Conjugates Efficiently Induce Hapten-Specific Antibodies which Recognize Both Streptococcus pneumoniae and Neisseria meningitidis: A Potent Multitarget Vaccine against Respiratory Infections JMCMA ; J. Med. Chem. ; 47-16(2004)3916...

5/3,K/35 (Item 1 from file: 266) Links

FEDRIP

Comp &amp; dist by NTIS, Intl Copyright All Rights Res. All rights reserved.

00614193

Identifying No.: 1Z0180003001-10 Agency Code: CRISP

Regulation of the Immune Response to Polysaccharides and

Principal Investigator: STEIN, K E

Sponsoring Org.: CENTER FOR BIOLOGICS EVALUATION AND RESEARCH - MONOCLONAL ANTIBODIES

Fy : 2002

Summary: ...and avidity. Simple PS not conjugated to protein (such as bacterial Levan, BL and Neisseria meningitidis group C, MCPs) elicit a thymus-independent (TI) response. PS conjugated to proteins (such as... ..analysis of mice immunized with commercial conjugate vaccines compared with mice immunized with fixed N. meningitidis showed the O-acetylation status of the PS moiety of conjugate vaccines determines the relative... ..with fixed bacteria, the conjugate vaccines elicit a greater IgG response including antibodies to both OAc+ and OAc- PS. Furthermore, the conjugates induce higher relative avidity IgG Abs of either equal reactivity on OAc+ or OAc- or higher OAc- reactivity. Our earlier studies showed that neonatal dendritic cells are functionally impaired in their ability...

Progress Report Summary:

5/3,K/36 (Item 2 from file: 266) Links

FEDRIP

Comp &amp; dist by NTIS, Intl Copyright All Rights Res. All rights reserved.

00613887

Identifying No.: 1Z01BJ002026-04 Agency Code: CRISP

Immunogenic determinants of Group A Meningococcal Polysaccharide

Principal Investigator: BASH, MARGARET C

Sponsoring Org.: CENTER FOR BIOLOGICS EVALUATION AND RESEARCH - BACTERIAL PRODUCTS

Fy : 2000

Immunogenic determinants of Group A Meningococcal Polysaccharide

Summary: Group A Meningococcal disease is a significant cause of morbidity and mortality world-wide. Epidemic disease continues to develop regularly in the meningitis belt of Africa and recent epidemics have also occurred in New Zealand and Saudi Arabia. In the U.S., meningococcal polysaccharide vaccine is administered to all military recruits and patients with functional or anatomic asplenia... similar studies using Haemophilus influenzae group B (HIB) conjugate vaccines followed by HIB polysaccharide, or Meningococcal group C conjugate vaccines followed by native group C meningococcal polysaccharide. Our initial studies are focused on assessing the immunological importance of the O-acetyl groups of the native Group A meningococcal polysaccharide. Group A polysaccharide was de-O-acetylated using alkaline hydrolysis. ELISA inhibition assays showed ... polysaccharide as they are by native polysaccharide suggesting the O-acetyl groups of group A meningococcal polysaccharide are immunologically important. Immunization of mice with OAC+ and OAC- Group A PS protein conjugate vaccines and OAC+ and OAC- PS vaccines have been completed. Analysis of the immune responses with ELISA and ELISA inhibition assays also suggests the OAC groups of meningococcal group A PS contribute to important antigenic epitopes of the PS. Bactericidal assays revealed high titer bactericidal activity in sera from mice immunized with OAC+ Group A PS conjugate vaccine and native OAC+ PS, but not in those immunized with OAC- conjugate or PS vaccine. The immunization studies have been repeated and confirmed our original findings.

Progress Report Summary:

Descriptors: acetylation; Neisseria meningitidis; hydrolysis; chemical structure function; immunity; immunoconjugate; enzyme linked immunosorbent assay; bacterial antigen; polysaccharide; Neisseria meningitidis vaccine

5/3,K/37 (Item 1 from file: 149) Links  
 TGG Health&Wellness DB(SM)  
 (c) 2009 Gale/Cengage. All rights reserved.  
 02948614 Supplier Number: 11112386 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
 W135 meningococcal disease in Africa (1).(Conference Summary)

Pollard, Andrew J.; Santamaria, Maria; Maiden, Martin C.J.  
 Emerging Infectious Diseases , 9 , 11 , 1503(2)  
 Nov ,  
 2003

Publication Format: Magazine/Journal  
 ISSN: 1080-6040  
 Language: English  
 Record Type: Fulltext Target Audience: Academic; Professional  
 Word Count: 1437 Line Count: 00128  
 W135 meningococcal disease in Africa (1).(Conference Summary)

Text:

Epidemic meningococcal disease has occurred in Africa for approximately 100 years and has been recognized as a particular problem in sub-Saharan Africa, "the meningitis belt," since 1963. Despite intervention with plain polysaccharide vaccines, thousands of cases and deaths continue...

...be important, including crowded living conditions, population movements, seasonal factors, and the characteristics of the meningococci circulating at a given time. During the latter half of the 20th century, serogroup A meningococci have been responsible for most epidemic disease in Africa; however, as with other regions of the world, cases caused by serogroup B, C, Y, W135, and X meningococci have been

meningogroupY.txt

occasionally responsible for epidemics. Some epidemic disease outbreaks have been associated with the annual Hajj pilgrimage (e.g., the spread of serogroup A meningococci during the late 1980s and the spread of W135 meningococci from 2000 onwards). Mass vaccination with serogroup A/C plain polysaccharide vaccines has been used...

...explored the scientific issues behind the design and implementation of a vaccine strategy for the meningitis belt of Africa focusing on the epidemiology of meningococcal isolates. Epidemiologic studies have provided an increasingly detailed knowledge of meningococcal disease in Africa. This knowledge has led to the identification of three distinct clonal complexes...

...by ST-1 and ST-5 complex. Recent epidemiologic findings have shown that serogroup A meningococci belonging to the ST-5 complex (ST-5 and ST-7) were still responsible for...

...serogroup C disease. However, while knowledge of the clonal complexes has provided important information on meningococcal disease in Africa, more detailed isolate characterization has shown that important diversity is overlooked by relying solely on sequence type. Despite the availability of a number of meningococcal typing strategies (including pulsed-field gel electrophoresis, multilocus enzyme electrophoresis, and 16S rRNA typing), to...

...of diversity and dynamics of these populations is an urgent requirement.

Since 2000, serogroup W135 meningococci (ST-11) have been isolated from sporadic cases in Algeria, Cameroon, Chad, Senegal, Niger, and...

...supporting enhanced laboratory surveillance throughout the region to monitor the spread of non-serogroup A meningococci. Polymerase chain reaction may increase case ascertainment, but basic microbiologic testing on a large scale...

...pilgrims returning from the Hajj. Since 2000 and the introduction of ST-11 complex, W135 meningococci among carried isolates in North Africa (Sudan, Morocco) was documented. By contrast, despite a small increase in cases associated with the Hajj, rates of disease caused by ST-11 W135 meningococci in Europe remained low since 2000, with some evidence that most activity was limited to...

...study found that the minority (8%) of W135 (case and carrier) isolates are O-acetylated (Oac+) in the United Kingdom and that the currently available tetravalent polysaccharide vaccine evokes bactericidal activity against both Oac+ and Oac- W135 and Y isolates. The relevance of O-acetylation to vaccine development remains uncertain.  
To...

...and C particularly) provide uncertainty about the future epidemiology of capsule expression during epidemics. Epidemic meningococcal disease in Africa might no longer be thought of as a peculiarity of serogroup A meningococci. The central idea from the workshop was that a comprehensive vaccine (i.e., a multivalent-conjugate) was the optimal approach to controlling epidemic disease in the meningitis belt of Africa. Even this approach may fail, given the remarkable adaptability of this variable...

...tetravalent ACYW conjugate vaccine for Africa, which, as outlined above, is an important objective. The Meningitis Vaccine Project will support the development of an affordable monovalent serogroup A conjugate polysaccharide vaccine...



# meningroupy.txt

...be achieved quickly. Discussion of the urgent issue of vaccines for control of epidemics of meningococcal disease in the next few years was not possible during the workshop. The current polysaccharide vaccine shortages raise the possibility that epidemic meningococcal disease continue with no intervention available. ACYW-conjugate vaccines are in development by several major...

...Africa, many more people might die before an affordable vaccine can be delivered by the Meningitis Vaccine Project.

## Acknowledgments

The authors are grateful to Dominique Caugant and Elisabeth Wedege for facilitating...

...Santamaria (WHO Headquarters/Geneva, Switzerland), P. Nicolas (WHO Collaborating Centre for Reference and Research on Meningococci/Marseilles, France), S. Handford (Communicable Disease Surveillance Centre (CDSC)), Public Health Laboratory Service, London, UK), M. Issa (Juba University, Sudan), E. Longworth (Public Health Laboratory Services, Meningococcal Reference Unit/Manchester, UK), S. Jacobsson (National Reference Laboratory for Pathogenic Neisseria/Orebro, Sweden), I...

...Berlin, Germany), B. Greenwood (London School of Hygiene and Tropical Medicine/London, UK), M. LaForce, (Meningitis Vaccine Project/Ferney Voltaire, France), A.J. Pollard (Oxford University, UK).

## Special Features:

### Descriptors:

...Meningococcal infections...

...Meningococcal infections...

...Meningococcal infections

### Geographic Codes:

? d s

Set	Items	Description
S1	25686	S (LOSS OR LACK) AND ACETYL
S2	169	S S1 AND MENIN?
S3	77	RD (unique items)
S4	124	S (MENIN? AND (OAC OR O-ACETYL))
S5	37	RD (unique items)

? s s5 and (Y or Group Y)

	37	S5
	2389570	Y
	10	GROUP Y
S6	8	S S5 AND (Y OR GROUP Y)

? s s4 and (Y or Group(w)Y)

### Processing

	124	S4
	2389570	Y
	11471029	GROUP
	2389570	Y
	2070	GROUP(w)Y

meningroupY.txt  
S7 10 S S4 AND (Y OR GROUP(W)Y)

? rd

>>>W: Duplicate detection is not supported for File 393.  
Duplicate detection is not supported for File 391.  
Records from unsupported files will be retained in the RD set.  
S8 8 RD (UNIQUE ITEMS)

? t s8/3,k/1-8

>>>W: KWIC option is not available in file(s): 399  
8/3,k/1 (Item 1 from file: 5) Links  
Fulltext available through: STIC Full Text Retrieval Options  
Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0019741080 Biosis No.: 200700400821

Protective meningococcal capsular polysaccharide epitopes and the role of O  
acetylation

Author: Fusco Peter C (Reprint); Farley Esme K; Huang Chun-Hsien; Moore Samuel;  
Michon Francis

Author Address: BioVeris Corp, 16020 Ind Dr, Gaithersburg, MD 20877 USA\*\*USA

Author E-mail Address: pfusco@bioveris.com; fmichon@bioveris.com

Journal: Clinical and Vaccine Immunology 14 ( 5 ): p 577-584 MAY 2007 2007

Item Identifier: doi:10.1128/CVI.00009-07

ISSN: 1556-6811

Document Type: Article

Record Type: Abstract

Language: English

Protective meningococcal capsular polysaccharide epitopes and the role of O  
acetylation

Abstract: Previous studies with group C meningococcal polysaccharide-tetanus toxoid  
(GCMP-TT) conjugates had suggested that the GCMP O-acetyl group masked the  
protective epitope for group C meningococci through steric hindrance or altered  
conformations. For this report, we confirmed this phenomenon and performed  
comparative studies with group Y meningococcal polysaccharide (GYMP)-TT to determine  
whether it might extend to other serogroups. The de-O... ..dOA) polysaccharides  
(PSS) resulted in higher serum bactericidal activities (SBA) towards the  
O-acetylated (OA) meningococcal strains from the respective serogroups.  
High-resolution H-nuclear magnetic resonance spectroscopy at 500 MHz...  
...generalized role for the O-acetyl group to provide an epitope of misdirected  
immunogenicity for meningococcal PS capsules, enabling escape from immune  
surveillance. In addition to greater chemical consistency, the dOA...

DESCRIPTORS:

Organisms: ...Neisseria meningitidis (Neisseriaceae...

Organisms: Parts Etc: ...meningococcal capsule

Diseases: meningococcal disease...

Mesh Terms: Meningococcal Infections (MeSH)

Chemicals & Biochemicals: ...O-acetyl... ...group Y meningococcal  
polysaccharide-TT

8/3,k/2 (Item 1 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts

(c) 2009 CSA. All rights reserved.

0000429006 IP Accession No: 1116875

Evaluation of two tetravalent (ACYW sub(135)) meningococcal vaccines in infants and  
small children: A clinical study comparing immunogenicity of O-acetyl-negative and  
O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Peltola, H; Safary, A; Kaehy, H; Karanko, V; Andre, FE Natl. Public Health Inst.,  
Page 34

meningroupy.txt  
Mannerheimintie 166, SF-00280 Helsinki 28, Finland  
Pediatrics , v 76 , n 1 , p 91-96 , 1985  
Addl. Source Info: Pediatrics, vol. 76, no. 1, pp. 91-96, 1985  
Publication Date: 1985

Document Type: Journal Article  
Record Type: Abstract  
Language: English  
Summary Language: English  
ISSN: 0031-4005  
File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts  
Evaluation of two tetravalent (ACYW sub(135)) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative...

Abstract:  
Two different tetravalent polysaccharide vaccines against group A, C, Y, and W sub(135) meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAc super(-)) and 78 the acetylated group C polysaccharide C(OAc super(+)) together with group A, Y, and W sub(135) polysaccharides. All polysaccharides, at a dose of 30 µg induced... responses were better in the older infants. The authors conclude that tetravalent (ACYW sub(135)) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations...

Descriptors: vaccines; immunogenicity; children; man; Neisseria meningitidis  
Identifiers:

8/3,k/3 (Item 1 from file: 34) Links  
Fulltext available through: STIC Full Text Retrieval Options  
SciSearch(R) Cited Ref Sci  
(C) 2009 The Thomson Corp. All rights reserved.  
12448577 Genuine Article#: 765uF No. References: 24  
Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD)

Author: Kao G; Tsai CM (REPRINT)  
Corporate Source: US FDA,Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Off Vaccine Res ,1401 Rockville Pike HFM-428/Rockville//MD/20852 (REPRINT); US FDA,Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Off Vaccine Res ,Rockville//MD/20852  
Journal: VACCINE , 2004 , v 22 , N3-4 ( JAN 2 ) , P 335-344  
ISSN: 0264-410X Publication date: 20040102  
Publisher: ELSEVIER SCI LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND  
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )  
Abstract: The O-acetyl groups in meningococcal A and typhoid Vi polysaccharides (PSS) are functional immunogenic epitopes in humans. To quantify and... groups in the PSS after these groups were hydrolyzed into anions. The O-acetylation in meningococcal A, C, Y and W-135, pneumococcal 9V and 18C and typhoid Vi PSS were analyzed. The O... The HPAEC method can quantify the O-acetyl content in 0.2 µg of the meningococcal C PS and has a sensitivity at least 10 times higher than that of the...  
Identifiers-- ...PULSED-AMPEROMETRIC DETECTION; NUCLEAR-MAGNETIC-RESONANCE; MENINGITIDIS SEROGROUP-A; PNEUMONIAE TYPE 9V; NEISSERIA- MENINGITIDIS; CAPSULAR POLYSACCHARIDE; STRUCTURAL DETERMINATION; GROUP-B; ANTIGENS; RESPONSES

8/3,k/4 (Item 2 from file: 34) Links  
Fulltext available through: STIC Full Text Retrieval Options  
Page 35

SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

11206251 Genuine Article#: 619Yt No. References: 44

Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from *Neisseria meningitidis* used in vaccine manufacture

Author: Jones C (REPRINT) ; Lemercinier X

Corporate Source: Natl Inst Biol Stand & Controls, Lab Mol Struct, Blanche Lane S  
Mimms/Potters Bar EN6 3QG/Herts/England/ (REPRINT); Natl Inst Biol Stand &

Controls, Lab Mol Struct, Potters Bar EN6 3QG/Herts/England/

Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, v 30, n4 (NOV 7), p 1233-1247

ISSN: 0731-7085 Publication date: 20021107

Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

...of NMR assays for the identity and O-acetyl content of capsular polysaccharides from *Neisseria meningitidis* used in vaccine manufacture

Abstract: ...nuclear magnetic resonance) spectroscopic assay for the identity of the capsular polysaccharides (CPSS) from *Neisseria meningitidis* Groups A, C, W135 and Y used in vaccine manufacture, and to determine the proportion of residues carrying an O-acetyl... ...and quantitation of the O-acetyl content are key control parameters for these vaccines. The meningococcal CPSS have variable levels of O-acetylation, present at multiple sites in the repeat unit... ...complex NMR spectra. Base-catalysed de-O-acetylation of the Groups A, C, W135 and Y CPSS yields simplified and reproducible spectra suitable for comparison with reference data. The degree of...

Identifiers-- ...GROUP-B POLYSACCHARIDE; NUCLEAR MAGNETIC-RESONANCE; CONJUGATE VACCINE; SEROGROUP-C; MENINGOCOCCAL POLYSACCHARIDE; BACTERIAL POLYSACCHARIDES; STRUCTURAL DETERMINATION; IMMUNOGENICITY; ANTIGENS; EPI TOPE

8/3,k/5 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0072801464 EMBASE No: 1985206880

Evaluation of two tetravalent (ACYW SUB 135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides

Peltola H.; Safary A.; Kayhty H.; et-al

Children's Hospital, University of Helsinki, Helsinki, Finland

Corresp. Author/Affil: : Children's Hospital, University of Helsinki, Helsinki, Finland

Pediatrics (PEDIATRICS) (United States) October 31, 1985, 76/1 (91-96)

CODEN: PEDIA ISSN: 0031-4005

Document Type: Journal Record Type: Abstract

Language: English

Evaluation of two tetravalent (ACYW SUB 135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative...

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W SUB 135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... ...first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAC SUP -) and 78 the acetylated group C polysaccharide C(OAC SUP +) together with group A, Y, and W SUB 135 polysaccharides. All polysaccharides, at a dose of 30 mug, induced antibody... ...38.5(deg)C (101.3(deg)F). We conclude that tetravalent (ACYW SUB 135) meningococcal vaccine is safe and immunologically effective in children younger than

meningroupY.txt

age 2 years. However, revaccinations...

Drug Descriptors:

\* bacterial antigen; \*meningococcus vaccine; \*polysaccharide

8/3,K/6 (Item 1 from file: 155) Links

Fulltext available through: STIC Full Text Retrieval Options

MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

07649693 PMID: 3925430

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Peltola H; Safary A; Kayhty H; Karanko V; Andre F E  
Pediatrics ( UNITED STATES ) Jul 1985 , 76 (1) p91-6 , ISSN: 0031-4005--Print  
Journal Code: 0376422

Publishing Model Print

Document type: Clinical Trial; Comparative Study; Journal Article; Randomized  
Controlled Trial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative...

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... First vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAc-) and 78 the acetylated group C polysaccharide C(OAc+) together with group A, Y, and W135 polysaccharides. All polysaccharides, at a dose of 30 micrograms, induced antibody responses after... fever exceeding 38.5 degrees C (101.3 degrees F). We conclude that tetravalent (ACYW135) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations... (

Descriptors: \*Bacterial Vaccines--therapeutic use--TU; \*Meningococcal Infections

--prevention and control--PC; \*Neisseria meningitidis--immunology --IM ;

...Antibodies, Bacterial--analysis--AN; Bacterial Vaccines--immunology--IM;

Double-Blind Method; Humans; Immunization, Secondary; Infant; Meningococcal

Vaccines; Time Factors

Named Person:

Chemical Name: Antibodies, Bacterial; Bacterial Vaccines; Meningococcal Vaccines

8/3,K/7 (Item 1 from file: 357) Links

Derwent Biotech Res.

(c) 2008 Thomson Reuters. All rights reserved.

0441686 DBA Accession No.: 2007-28544 PATENT

New 1,2,4-triazol-1-yl bisphenyl derivatives useful for treatment of e.g. cancer, autoimmune disorders, or inflammatory disorders employing 1,2,4-triazol-1-yl bisphenyl derivative, an aromatase-inhibitor, sulfatase-inhibitor, for use in treating cancer, inflammation, fever, anorexia, HIV virus infection, autoimmune disease, cerebral ischemia, osteoarthritis, rheumatoid arthritis, asthma, multiple sclerosis, Alzheimer disease, atherosclerosis, stroke, Crohn disease, psoriasis, hemophilia

Author: WOO L W L; JACKSON T; PUROHIT A; REED M J; POTTER B V L

Patent Assignee: STERIX LTD 2007

Patent Number: WO 200768905 Patent Date: 20070621 WPI Accession No.: 2007-859773

( 200779 )

Priority Application Number: GB 200525323 Application Date: 20051213

National Application Number: WO 2006GB4630 Application Date: 20061212

Language: English

meningroupy.txt

Abstract: ...4-Triazol-1-yl bisphenyl derivatives of formula (I) are new. R3 - R7=H or -Y'-R8; R8=OH, hydrocarbyl, oxyhydrocarbyl, cyano, nitro, H-bond acceptors, halo, heterocyclic ring (optionally substituted) or phenyl (substituted by amino); X=bond or a linker group; Y'=optional linker group; R9=H, OH or -OSO2NR1R2; R1 and R2=H or hydrocarbyl. At least one of R3, R4, R5, R6 and R7 is -Y'-R8 in which R8 is heterocyclic ring (optionally substituted) or phenyl (substituted by amino). Either... ..is a bond and at least one of R3, R4, R5, R6 and R7 is -Y'-R8; or (b) R9 is -OSO2NR1R2 or -OH and four of R3, R4, R5, R6 and R7 are H and one of R3, R4, R5, R6 and R7 is -Y'-R8. ACTIVITY - Cytostatic; Endocrine-Gen.; Antiinflammatory; Dermatological; Antipyretic; Cardiovascular-Gen.; Hemostatic; Anticoagulant; Immunomodulator; Anabolic; Eating... ..anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine; angiogenesis, metastases, cerebral ischemia, ischemic heart disease, osteoarthritis, rheumatoid arthritis, asthma, multiple sclerosis, neurodegeneration... ..hydroxyphenylboronic acid (.174 g), K2CO3 (0.29 g), tetrabutylammonium bromide (TBAB) (0.279 g), Pd(OAc)2 (0.005 - 0.006 g) in ethanol (1.5 ml) and water (3.5...  
E.C. Numbers:

8/3,K/8 (Item 1 from file: 149) Links  
TGG Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.  
02948614 Supplier Number: 111112386 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
w135 meningococcal disease in Africa (1).(Conference Summary)

Pollard, Andrew J.; Santamaria, Maria; Maiden, Martin C.J.  
Emerging Infectious Diseases , 9 , 11 , 1503(2)  
Nov,  
2003

Publication Format: Magazine/Journal  
ISSN: 1080-6040  
Language: English  
Record Type: Fulltext Target Audience: Academic; Professional  
Word Count: 1437 Line Count: 00128  
w135 meningococcal disease in Africa (1).(Conference Summary)

Text:

Epidemic meningococcal disease has occurred in Africa for approximately 100 years and has been recognized as a particular problem in sub-Saharan Africa, "the meningitis belt," since 1963. Despite intervention with plain polysaccharide vaccines, thousands of cases and deaths continue...

...be important, including crowded living conditions, population movements, seasonal factors, and the characteristics of the meningococci circulating at a given time. During the latter half of the 20th century, serogroup A meningococci have been responsible for most epidemic disease in Africa; however, as with other regions of the world, cases caused by serogroup B, C, Y, w135, and X meningococci have been occasionally responsible for epidemics. Some epidemic disease outbreaks have been associated with the annual Hajj pilgrimage (e.g., the spread of serogroup A meningococci during the late 1980s and the spread of w135 meningococci from 2000 onwards). Mass vaccination with serogroup A/C plain polysaccharide vaccines has been used...

...explored the scientific issues behind the design and implementation of a vaccine strategy for the meningitis belt of Africa focusing on the

epidemiology of meningococcal isolates. Epidemiologic studies have provided an increasingly detailed knowledge of meningococcal disease in Africa. This knowledge has led to the identification of three distinct clonal complexes...

...by ST-1 and ST-5 complex. Recent epidemiologic findings have shown that serogroup A meningococci belonging to the ST-5 complex (ST-5 and ST-7) were still responsible for...

...serogroup C disease. However, while knowledge of the clonal complexes has provided important information on meningococcal disease in Africa, more detailed isolate characterization has shown that important diversity is overlooked by relying solely on sequence type. Despite the availability of a number of meningococcal typing strategies (including pulsed-field gel electrophoresis, multilocus enzyme electrophoresis, and 16S rRNA typing), to...

...of diversity and dynamics of these populations is an urgent requirement. Since 2000, serogroup W135 meningococci (ST-11) have been isolated from sporadic cases in Algeria, Cameroon, Chad, Senegal, Niger, and...

...supporting enhanced laboratory surveillance throughout the region to monitor the spread of non-serogroup A meningococci. Polymerase chain reaction may increase case ascertainment, but basic microbiologic testing on a large scale...

...pilgrims returning from the Hajj. Since 2000 and the introduction of ST-11 complex, W135 meningococci among carried isolates in North Africa (Sudan, Morocco) was documented. By contrast, despite a small increase in cases associated with the Hajj, rates of disease caused by ST-11 W135 meningococci in Europe remained low since 2000, with some evidence that most activity was limited to...

...study found that the minority (8%) of W135 (case and carrier) isolates are O-acetylated (Oac+) in the United Kingdom and that the currently available tetravalent polysaccharide vaccine evokes bactericidal activity against both Oac+ and Oac- W135 and Y isolates. The relevance of O-acetylation to vaccine development remains uncertain.

To plan intervention strategies...

...and C particularly) provide uncertainty about the future epidemiology of capsule expression during epidemics. Epidemic meningococcal disease in Africa might no longer be thought of as a peculiarity of serogroup A meningococci. The central idea from the workshop was that a comprehensive vaccine (i.e., a multivalent-conjugate) was the optimal approach to controlling epidemic disease in the meningitis belt of Africa. Even this approach may fail, given the remarkable adaptability of this variable...

...tetravalent ACYW conjugate vaccine for Africa, which, as outlined above, is an important objective. The Meningitis Vaccine Project will support the development of an affordable monovalent serogroup A conjugate polysaccharide vaccine...

...be achieved quickly. Discussion of the urgent issue of vaccines for control of epidemics of meningococcal disease in the next few years was not possible during the workshop. The current polysaccharide vaccine shortages raise the possibility that epidemic meningococcal disease continue with no intervention available. ACYW-conjugate vaccines are in development by several major...

...Africa, many more people might die before an affordable vaccine can be delivered by the Meningitis Vaccine Project.

## Acknowledgments

The authors are grateful to Dominique Caugant and Elisabeth Wedege for facilitating...

...Santamaria (WHO Headquarters/Geneva, Switzerland), P. Nicolas (WHO Collaborating Centre for Reference and Research on Meningococci/Marseilles, France), S. Handford (Communicable Disease Surveillance Centre (CDSC)), Public Health Laboratory Service, London, UK), M. Issa (Juba University, Sudan), E. Longworth (Public Health Laboratory Services, Meningococcal Reference Unit/Manchester, UK), S. Jacobsson (National Reference Laboratory for Pathogenic Neisseria/Orebro, Sweden), I...

...Berlin, Germany), B. Greenwood (London School of Hygiene and Tropical Medicine/London, UK), M. LaForce, (Meningitis Vaccine Project/Ferney Voltaire, France), A.J. Pollard (Oxford University, UK).

## Special Features:

## Descriptors:

...Meningococcal infections...

...Meningococcal infections...

...Meningococcal infections

## Geographic Codes:

? d s

Set	Items	Description
S1	25686	S (LOSS OR LACK) AND ACETYL
S2	169	S S1 AND MENIN?
S3	77	RD (unique items)
S4	124	S (MENIN? AND (OAC OR O-ACETYL))
S5	37	RD (unique items)
S6	8	S S5 AND (Y OR GROUP Y)
S7	10	S S4 AND (Y OR GROUP(W)Y)
S8	8	RD (unique items)

? t s6/3,k/1-8

>>>W: KWIC option is not available in file(s): 399

6/3,k/1 (Item 1 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0019741080 Biosis No.: 200700400821

Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation

Author: Fusco Peter C (Reprint); Farley Esme K; Huang Chun-Hsien; Moore Samuel; Michon Francis

Author Address: BioVeris Corp, 16020 Ind Dr, Gaithersburg, MD 20877 USA\*\*USA

Author E-mail Address: pfusco@bioveris.com; fmichon@bioveris.com

Journal: Clinical and Vaccine Immunology 14 ( 5 ): p 577-584 MAY 2007 2007

Item Identifier: doi:10.1128/CVI.00009-07

ISSN: 1556-6811

Document Type: Article

Record Type: Abstract

Language: English

Protective meningococcal capsular polysaccharide epitopes and the role of O



**Abstract:** Previous studies with group C meningococcal polysaccharide-tetanus toxoid (GCMP-TT) conjugates had suggested that the GCMP O-acetyl group masked the protective epitope for group C meningococci through steric hindrance or altered conformations. For this report, we confirmed this phenomenon and performed comparative studies with group Y meningococcal polysaccharide (GYMP)-TT to determine whether it might extend to other serogroups. The de-O... ..dOA) polysaccharides (PSS) resulted in higher serum bactericidal activities (SBA) towards the O-acetylated (OA) meningococcal strains from the respective serogroups. High-resolution H-nuclear magnetic resonance spectroscopy at 500 MHz... ..generalized role for the O-acetyl group to provide an epitope of misdirected immunogenicity for meningococcal PS capsules, enabling escape from immune surveillance. In addition to greater chemical consistency, the dOA...  
**DESCRIPTORS:**  
Organisms: ...Neisseria meningitidis (Neisseriaceae...  
Organisms: Parts Etc: ...meningococcal capsule  
Diseases: meningococcal disease...  
Mesh Terms: Meningococcal Infections (MeSH)  
Chemicals & Biochemicals: ...O-acetyl... ..group Y meningococcal polysaccharide-TT

6/3,K/2 (Item 1 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts

(c) 2009 CSA. All rights reserved.

0000429006 IP Accession No: 1116875

Evaluation of two tetravalent (ACYW sub(135)) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Peltola, H; Safary, A; Kaeyhty, H; Karanko, V; Andre, FE Natl. Public Health Inst., Mannerheimintie 166, SF-00280 Helsinki 28, Finland  
Pediatrics, v 76, n 1, p 91-96, 1985

Add. Source Info: Pediatrics, vol. 76, no. 1, pp. 91-96, 1985

Publication Date: 1985

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English

ISSN: 0031-4005

File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts

Evaluation of two tetravalent (ACYW sub(135)) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative...

**Abstract:**

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W sub(135) meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... ..first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAc super(-)) and 78 the acetylated group C polysaccharide C(OAc super(+)) together with group A, Y, and W sub(135) polysaccharides. All polysaccharides, at a dose of 30 mu g induced... ..responses were better in the older infants. The authors conclude that tetravalent (ACYW sub(135)) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations...

**Descriptors:** vaccines; immunogenicity; children; man; Neisseria meningitidis

**Identifiers:**

6/3,k/3 (Item 1 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options  
SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

12448577 Genuine Article#: 765UF No. References: 24

Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD)

Author: Kao G; Tsai CM (REPRINT)

Corporate Source: US FDA,Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Off Vaccine Res ,1401 Rockville Pike HFM-428/Rockville//MD/20852 (REPRINT); US FDA,Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Off Vaccine Res ,Rockville//MD/20852

Journal: VACCINE , 2004 , v 22 , N3-4 ( JAN 2 ) , P 335-344

ISSN: 0264-410X Publication date: 20040102

Publisher: ELSEVIER SCI LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND

Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )

Abstract: The O-acetyl groups in meningococcal A and typhoid Vi polysaccharides (PSS) are functional immunogenic epitopes in humans. To quantify and... groups in the PSS after these groups were hydrolyzed into anions. The O-acetylation in meningococcal A, C, Y and W-135, pneumococcal 9v and 18C and typhoid Vi PSS were analyzed. The O... The HPAEC method can quantify the O-acetyl content in 0.2 mug of the meningococcal C PS and has a sensitivity at least 10 times higher than that of the...

Identifiers-- ...PULSED-AMPEROMETRIC DETECTION; NUCLEAR-MAGNETIC-RESONANCE; MENINGITIDIS SEROGROUP-A; PNEUMONIAE TYPE 9V; NEISSERIA- MENINGITIDIS; CAPSULAR POLYSACCHARIDE; STRUCTURAL DETERMINATION; GROUP-B; ANTIGENS; RESPONSES

6/3,k/4 (Item 2 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options  
SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

11206251 Genuine Article#: 619YI No. References: 44

Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture

Author: Jones C (REPRINT); Lemerclinier X

Corporate Source: Natl Inst Biol Stand & Controls,Lab Mol Struct,Blanche Lane S Minns/Potters Bar EN6 3QG/Herts/England/ (REPRINT); Natl Inst Biol Stand & Controls,Lab Mol Struct,Potters Bar EN6 3QG/Herts/England/

Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS , 2002 , v 30 , N4 ( NOV 7 ) , P 1233-1247

ISSN: 0731-7085 Publication date: 20021107

Publisher: PERGAMON-ELSEVIER SCIENCE LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND

Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )

...of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture

Abstract: ...nuclear magnetic resonance) spectroscopic assay for the identity of the capsular polysaccharides (CPSS) from Neisseria meningitidis Groups A, C, W135 and Y used in vaccine manufacture, and to determine the proportion of residues carrying an O-acetyl... and quantitation of the O-acetyl content are key control parameters for these vaccines. The meningococcal CPSS have variable levels of O-acetylation, present at multiple sites in the repeat unit... complex NMR spectra. Base-catalysed de-O-acetylation of the Groups A, C, W135 and Y CPSS yields simplified and reproducible spectra suitable for comparison with reference data. The degree of...

Identifiers-- ...GROUP-B POLYSACCHARIDE; NUCLEAR MAGNETIC-RESONANCE; CONJUGATE

meningroupy.txt

VACCINE; SEROGROUP-C; MENINGOCOCCAL POLYSACCHARIDE; BACTERIAL POLYSACCHARIDES;  
STRUCTURAL DETERMINATION; IMMUNOGENICITY; ANTIGENS; EPIOTOPE

6/3,K/5 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0072801464 EMBASE No: 1985206880

Evaluation of two tetravalent (ACYW SUB 135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides

Peltola H.; Safary A.; Kayhty H.; et-al  
Children's Hospital, University of Helsinki, Helsinki, Finland  
Corresp. Author/Affil: : Children's Hospital, University of Helsinki, Helsinki, Finland

Pediatrics ( PEDIATRICS ) ( United States ) October 31, 1985 , 76/1 (91-96)

CODEN: PEDIA ISSN: 0031-4005

Document Type: Journal Record Type: Abstract

Language: English

Evaluation of two tetravalent (ACYW SUB 135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative...

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W SUB 135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAC SUP -) and 78 the acetylated group C polysaccharide C(OAC SUP +) together with group A, Y, and W SUB 135 polysaccharides. All polysaccharides, at a dose of 30 mug, induced antibody... 38.5(deg)C (101.3(deg)F). We conclude that tetravalent (ACYW SUB 135) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations...

Drug Descriptors:

\* bacterial antigen; \*meningococcus vaccine; \*polysaccharide

6/3,K/6 (Item 1 from file: 155) Links

Fulltext available through: STIC Full Text Retrieval Options

MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

07649693 PMID: 3925430

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Peltola H; Safary A; Kayhty H; Karanko V; Andre F E  
Pediatrics ( UNITED STATES ) Jul 1985 , 76 (1) p91-6 , ISSN: 0031-4005--Print

Journal Code: 0376422

Publishing Model Print

Document type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative...

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered... first vaccination. Forty of the infants received vaccine

meningroupy.txt

containing the nonacetylated group C polysaccharide C(OAC-) and 78 the acetylated group C polysaccharide C(OAC+) together with group A, Y, and W135 polysaccharides. All polysaccharides, at a dose of 30 micrograms, induced antibody responses after... fever exceeding 38.5 degrees C (101.3 degrees F). We conclude that tetravalent (ACYW135) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations... ( Descriptors: \*Bacterial Vaccines--therapeutic use--TU; \*Meningococcal Infections --prevention and control--PC; \*Neisseria meningitidis--immunology --IM ; ...Antibodies, Bacterial--analysis--AN; Bacterial Vaccines--immunology--IM; Double-Blind Method; Humans; Immunization, Secondary; Infant; Meningococcal Vaccines; Time Factors  
Named Person:  
Chemical Name: Antibodies, Bacterial; Bacterial Vaccines; Meningococcal Vaccines

6/3,K/7 (Item 1 from file: 357) Links  
Derwent Biotech Res.

(c) 2008 Thomson Reuters. All rights reserved.

0441686 DBA Accession No.: 2007-28544 PATENT

New 1,2,4-triazol-1-yl bisphenyl derivatives useful for treatment of e.g. cancer, autoimmune disorders, or inflammatory disorders employing 1,2,4-triazol-1-yl bisphenyl derivative, an aromatase-inhibitor, sulfatase-inhibitor, for use in treating cancer, inflammation, fever, anorexia, HIV virus infection, autoimmune disease, cerebral ischemia, osteoarthritis, rheumatoid arthritis, asthma, multiple sclerosis, Alzheimer disease, atherosclerosis, stroke, Crohn disease, psoriasis, hemophilia

Author: WOO L W L; JACKSON T; PUROHIT A; REED M J; POTTER B V L

Patent Assignee: STERIX LTD 2007

Patent Number: WO 200768905 Patent Date: 20070621 WPI Accession No.: 2007-859773 ( 200779 )

Priority Application Number: GB 200525323 Application Date: 20051213

National Application Number: WO 2006GB4630 Application Date: 20061212

Language: English

Abstract: ...4-Triazol-1-yl bisphenyl derivatives of formula (I) are new. R3 - R7=H or -Y'-R8; R8=OH, hydrocarbyl, oxyhydrocarbyl, cyano, nitro, H-bond acceptors, halo, heterocyclic ring (optionally substituted) or phenyl (substituted by amino); X=bond or a linker group; Y'=optional linker group; R9=H, OH or -OSO2NR1R2; R1 and R2=H or hydrocarbyl. At least one of R3, R4, R5, R6 and R7 is -Y'-R8 in which R8 is heterocyclic ring (optionally substituted) or phenyl (substituted by amino). Either... is a bond and at least one of R3, R4, R5, R6 and R7 is -Y'-R8; or (b) R9 is -OSO2NR1R2 or -OH and four of R3, R4, R5, R6 and R7 are H and one of R3, R4, R5, R6 and R7 is -Y'-R8. ACTIVITY - Cytostatic; Endocrine-Gen.; Antiinflammatory; Dermatological; Antipyretic; Cardiovascular-Gen.; Hemostatic; Anticoagulant; Immunomodulator; Anabolic; Eating... anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine; angiogenesis, metastases, cerebral ischemia, ischemic heart disease, osteoarthritis, rheumatoid arthritis, asthma, multiple sclerosis, neurodegeneration... hydroxyphenylboronic acid (.174 g), K2CO3 (0.29 g), tetrabutylammonium bromide (TBAB) (0.279 g), Pd(OAC)2 (0.005 - 0.006 g) in ethanol (1.5 ml) and water (3.5...  
E.C. Numbers:

6/3,K/8 (Item 1 from file: 149) Links

TGG Health&wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02948614 Supplier Number: 11112386 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
w135 meningococcal disease in Africa (1).(Conference Summary)

Pollard, Andrew J.; Santamaria, Maria; Maiden, Martin C.J.

Emerging Infectious Diseases , 9 , 11 , 1503(2)

NOV ,

2003

Publication Format: Magazine/Journal

ISSN: 1080-6040

Language: English

Record Type: Fulltext Target Audience: Academic; Professional

Word Count: 1437 Line Count: 00128

w135 meningococcal disease in Africa (1).(Conference Summary)

Text:

Epidemic meningococcal disease has occurred in Africa for approximately 100 years and has been recognized as a particular problem in sub-Saharan Africa, "the meningitis belt," since 1963. Despite intervention with plain polysaccharide vaccines, thousands of cases and deaths continue...

...be important, including crowded living conditions, population movements, seasonal factors, and the characteristics of the meningococci circulating at a given time. During the latter half of the 20th century, serogroup A meningococci have been responsible for most epidemic disease in Africa; however, as with other regions of the world, cases caused by serogroup B, C, Y, w135, and X meningococci have been occasionally responsible for epidemics. Some epidemic disease outbreaks have been associated with the annual Hajj pilgrimage (e.g., the spread of serogroup A meningococci during the late 1980s and the spread of w135 meningococci from 2000 onwards). Mass vaccination with serogroup A/C plain polysaccharide vaccines has been used...

...explored the scientific issues behind the design and implementation of a vaccine strategy for the meningitis belt of Africa focusing on the epidemiology of meningococcal isolates. Epidemiologic studies have provided an increasingly detailed knowledge of meningococcal disease in Africa. This knowledge has led to the identification of three distinct clonal complexes...

...by ST-1 and ST-5 complex. Recent epidemiologic findings have shown that serogroup A meningococci belonging to the ST-5 complex (ST-5 and ST-7) were still responsible for...

...serogroup C disease. However, while knowledge of the clonal complexes has provided important information on meningococcal disease in Africa, more detailed isolate characterization has shown that important diversity is overlooked by relying solely on sequence type. Despite the availability of a number of meningococcal typing strategies (including pulsed-field gel electrophoresis, multilocus enzyme electrophoresis, and 16s rRNA typing), to...

...of diversity and dynamics of these populations is an urgent requirement.

Since 2000, serogroup w135 meningococci (ST-11) have been isolated from sporadic cases in Algeria, Cameroon, Chad, Senegal, Niger, and...

...supporting enhanced laboratory surveillance throughout the region to monitor the spread of non-serogroup A meningococci. Polymerase chain reaction may increase case ascertainment, but basic microbiologic testing on a large scale...

...pilgrims returning from the Hajj. Since 2000 and the introduction of ST-11 complex, w135 meningococci among carried isolates in North Africa (Sudan, Morocco) was documented. By contrast, despite a small

increase in cases associated with the Hajj, rates of disease caused by ST-11 W135 meningococci in Europe remained low since 2000, with some evidence that most activity was limited to...

...study found that the minority (8%) of W135 (case and carrier) isolates are O-acetylated (Oac+) in the United Kingdom and that the currently available tetravalent polysaccharide vaccine evokes bactericidal activity against both Oac+ and Oac- W135 and Y isolates. The relevance of O-acetylation to vaccine development remains uncertain.

To plan intervention strategies...

...and C particularly) provide uncertainty about the future epidemiology of capsule expression during epidemics. Epidemic meningococcal disease in Africa might no longer be thought of as a peculiarity of serogroup A meningococci. The central idea from the workshop was that a comprehensive vaccine (i.e., a multivalent-conjugate) was the optimal approach to controlling epidemic disease in the meningitis belt of Africa. Even this approach may fail, given the remarkable adaptability of this variable...

...tetravalent ACYW conjugate vaccine for Africa, which, as outlined above, is an important objective. The Meningitis Vaccine Project will support the development of an affordable monovalent serogroup A conjugate polysaccharide vaccine...

...be achieved quickly. Discussion of the urgent issue of vaccines for control of epidemics of meningococcal disease in the next few years was not possible during the workshop. The current polysaccharide vaccine shortages raise the possibility that epidemic meningococcal disease continue with no intervention available. ACYW-conjugate vaccines are in development by several major...

...Africa, many more people might die before an affordable vaccine can be delivered by the Meningitis Vaccine Project.

#### Acknowledgments

The authors are grateful to Dominique Caugant and Elisabeth Wedege for facilitating...

...Santamaria (WHO Headquarters/Geneva, Switzerland), P. Nicolas (WHO Collaborating Centre for Reference and Research on Meningococci/Marseilles, France), S. Handford (Communicable Disease Surveillance Centre (CDSC)), Public Health Laboratory Service, London, UK), M. Issa (Juba University, Sudan), E. Longworth (Public Health Laboratory Services, Meningococcal Reference Unit/Manchester, UK), S. Jacobsson (National Reference Laboratory for Pathogenic Neisseria/Örebro, Sweden), I...

...Berlin, Germany), B. Greenwood (London School of Hygiene and Tropical Medicine/London, UK), M. LaForce, (Meningitis Vaccine Project/Ferney Voltaire, France), A.J. Pollard (Oxford University, UK).

#### Special Features:

##### Descriptors:

...Meningococcal infections...

...Meningococcal infections...

...Meningococcal infections

##### Geographic Codes:

meningroupy.txt

```
? d s
Set      Items  Description
S1       25686  S (LOSS OR LACK) AND ACETYL
S2       169   S S1 AND MENIN?
S3       77    RD (unique items)
S4       124   S (MENIN? AND (OAC OR O-ACETYL))
S5       37    RD (unique items)
S6       8     S S5 AND (Y OR GROUP Y)
S7       10    S S4 AND (Y OR GROUP(W)Y)
S8       8     RD (unique items)

? s ((o-acetyl(w)positive) and menin? and (Y or Group(w)Y))
Processing
Processing 181    O-ACETYL
           6748449 POSITIVE
           0      O-ACETYL(W)POSITIVE
           556587  MENIN?
           2389570 Y
           11471029 GROUP
           2389570 Y
           2070   GROUP(W)Y
S9         0      S ((O-ACETYL(W)POSITIVE) AND MENIN? AND (Y OR GROUP(W)Y))

? s ((O-aceyl(w)negative) and menin? and (Y or Group(w)Y))
Processing
           0      O-ACEYTL
           5193913 NEGATIVE
           0      O-ACEYTL(W)NEGATIVE
           556587  MENIN?
           2389570 Y
           11471029 GROUP
           2389570 Y
           2070   GROUP(W)Y
S10        0      S ((O-ACEYTL(W)NEGATIVE) AND MENIN? AND (Y OR GROUP(W)Y))

? d s
Set      Items  Description
S1       25686  S (LOSS OR LACK) AND ACETYL
S2       169   S S1 AND MENIN?
S3       77    RD (unique items)
S4       124   S (MENIN? AND (OAC OR O-ACETYL))
S5       37    RD (unique items)
S6       8     S S5 AND (Y OR GROUP Y)
S7       10    S S4 AND (Y OR GROUP(W)Y)
S8       8     RD (unique items)
S9       0     S ((O-ACETYL(W)POSITIVE) AND MENIN? AND (Y OR GROUP(W)Y))
S10      0     S ((O-ACEYTL(W)NEGATIVE) AND MENIN? AND (Y OR GROUP(W)Y))

?
```